6.01.33 Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders

Original Policy Date: February 13, 2002
Effective Date: February 1, 2024
Section: 6.0 Radiology
Page: Page 1 of 58

Policy Statement

I. Wireless capsule endoscopy of the small bowel may be considered medically necessary when both of the following conditions are met:
   A. When the procedure is NOT intended for all of the below:
      1. To evaluate the extent of involvement of known Crohn disease or ulcerative colitis
      2. To evaluate the esophagus, in individuals with gastroesophageal reflux or other esophageal pathologies
      3. To evaluate other gastrointestinal (GI) diseases and conditions not presenting with GI bleeding, including but not limited to, celiac sprue, irritable bowel syndrome, lynch syndrome (risk for hereditary nonpolyposis colorectal cancer), portal hypertensive enteropathy, small bowel neoplasm, screening for colonic polyps or cancer and unexplained chronic abdominal pain
      4. For initial evaluation of individuals with acute upper GI bleeding
      5. To evaluate individuals with evidence of lower GI bleeding and major risks for colonoscopy or moderate sedation
      6. To evaluate individuals following incomplete colonoscopy
   B. If the procedure is intended for any of the below:
      1. Suspected small bowel bleeding, and both of the following:
         a. Inconclusive upper gastrointestinal (GI) endoscopy during the current episode of illness
         b. Inconclusive lower GI endoscopy (colonoscopy) during the current episode of illness
      2. Initial diagnosis in individuals with suspected Crohn disease without evidence of disease on conventional diagnostic tests (such as small bowel follow-through [SBFT] and upper and lower endoscopy)
      3. Established diagnosis of Crohn disease, with unexpected change(s) in the course of disease or response to treatment, suggesting the initial diagnosis may be incorrect and reexamination may be indicated
      4. For surveillance of the small bowel in individuals with hereditary GI polyposis syndromes, including familial adenomatous polyposis and Peutz-Jeghers syndrome

II. Wireless Capsule Endoscopy is considered investigational if the patient’s situation does not meet the criteria above.

III. The patency capsule is considered investigational, including use to evaluate patency of the GI tract before wireless capsule endoscopy.

IV. Magnetic capsule endoscopy is considered investigational for the evaluation of individuals with unexplained upper abdominal complaints and all other indications.

NOTE: Refer to Appendix A to see the policy statement changes (if any) from the previous version.

Policy Guidelines

Suspected small bowel bleeding, previously referred to as obscure gastrointestinal (GI) tract bleeding is defined as recurrent or persistent iron-deficiency anemia: positive fecal occult blood test; or visible bleeding with no bleeding source found at original endoscopy.
Coding
The following CPT code specifically describes the use of the capsule camera:
- **91110**: Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus through ileum, with interpretation and report

The following CPT code is also specific to capsule endoscopy of the esophagus alone:
- **91111**: Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with interpretation and report

The following is a category III CPT code for capsule endoscopy of the esophagus and stomach:
- **0651T**: Magnetically controlled capsule endoscopy, esophagus through stomach, including intraprocedural positioning of capsule, with interpretation and report

This new Category 1 code was created to replace Category III code 0355T:
- **91113**: Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), colon, with interpretation and report

Description
The wireless capsule endoscopy (CE) uses a noninvasive device to visualize segments of the gastrointestinal (GI) tract. Patients swallow a capsule that records images of the intestinal mucosa as it passes through the GI tract. The capsule is collected after being excreted and images are interpreted.

Related Policies
- N/A

Benefit Application
Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status
Table 1 summarizes various wireless CE devices with clearance by the FDA.

Code used: NEZ

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Date Cleared</th>
<th>510(k) No.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pillcam SB 3 Capsule Endoscopy System, Pillcam</td>
<td>Given Imaging Ltd.</td>
<td>8/27/2021</td>
<td>K211684</td>
<td>For visualization of the small bowel mucosa. It may be used in the visualization and monitoring of: lesions that may indicate Crohn’s disease not detected by upper and lower endoscopy; lesions that may be a source of obscure bleeding not detected by upper and lower endoscopy; lesions that</td>
</tr>
<tr>
<td>Device</td>
<td>Manufacturer</td>
<td>Date Cleared</td>
<td>510(k) No.</td>
<td>Indication</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>NaviCam Stomach Capsule System</td>
<td>AnX Robotica, Inc.</td>
<td>5/22/2020</td>
<td>K203192</td>
<td>For visualization of the stomach of adults (≥22 years) with a body mass index &lt;38. The system can be used in clinics and hospitals, including emergency room settings.</td>
</tr>
<tr>
<td>CapsoCam Plus (SV-3)</td>
<td>CapsoVision Inc.</td>
<td>4/19/2019</td>
<td>K183192</td>
<td>For visualization of the small bowel mucosa in adults. It may be used as a tool in the detection of abnormalities of the small bowel.</td>
</tr>
<tr>
<td>Olympus Small Intestinal Capsule Endoscope System</td>
<td>Olympus Medical Systems Corp.</td>
<td>3/5/2019</td>
<td>K183053</td>
<td>For visualization of the small intestine mucosa.</td>
</tr>
<tr>
<td>MiroCam Capsule Endoscope System</td>
<td>IntroMedic Co. Ltd.</td>
<td>11/8/2018</td>
<td>K180732</td>
<td>May be used as a tool in the detection of abnormalities of the small bowel and this device is indicated for adults and children from 2 years of age.</td>
</tr>
<tr>
<td>Olympus Small Intestinal Capsule Endoscope System</td>
<td>Olympus Medical Systems Corp.</td>
<td>3/13/2018</td>
<td>K173459</td>
<td>May be used in the visualization and monitoring of lesions that may indicate Crohn’s disease not detected by upper and lower endoscopy. - It may be used in the visualization and monitoring of lesions that may be a source of obscure bleeding (either overt or occult) not detected by upper and lower endoscopy. It may be used in the visualization and monitoring of lesions that may be potential causes of iron deficiency anemia (IDA) not detected by upper and lower endoscopy. The Red Color Detection Function is intended to mark frames of the video suspected of containing blood or red areas.</td>
</tr>
<tr>
<td>PillCam Patency System</td>
<td>Given Imaging Ltd.</td>
<td>3/8/2018</td>
<td>K180171</td>
<td>Intended to verify adequate patency of the gastrointestinal tract prior to administration of the PillCam video capsule in patients with known or suspected strictures.</td>
</tr>
<tr>
<td>MiroCam Capsule Endoscope System</td>
<td>IntroMedic Co. Ltd.</td>
<td>1/30/2018</td>
<td>K170438</td>
<td>For visualization of the small intestine mucosa.</td>
</tr>
<tr>
<td>PillCam SBC capsule endoscopy system</td>
<td>Given Imaging Ltd.</td>
<td>9/1/2017</td>
<td>K170210</td>
<td>For visualization of the small intestine mucosa.</td>
</tr>
<tr>
<td>RAPID Web</td>
<td>Given Imaging Ltd.</td>
<td>5/26/2017</td>
<td>K170839</td>
<td>Intended for visualization of the small bowel mucosa.</td>
</tr>
<tr>
<td>AdvanCE capsule endoscope delivery device</td>
<td>United States Endoscopy Group Inc.</td>
<td>3/10/2017</td>
<td>K163495</td>
<td>Intended for visualization of the small bowel mucosa.</td>
</tr>
<tr>
<td>Olympus Small Intestinal Capsule Endoscope System</td>
<td>OLYMPUS MEDICAL SYSTEMS CORP.</td>
<td>1/19/2017</td>
<td>K163069</td>
<td>Intended for visualization of the small bowel mucosa.</td>
</tr>
</tbody>
</table>
### Background

**Wireless Capsule Endoscopy**

Wireless capsule endoscopy (CE) is performed using the PillCam Given Diagnostic Imaging System (previously called M2A), which is a disposable imaging capsule manufactured by Given Imaging. The capsule measures 11 by 30 mm and contains video imaging, self-illumination, and image transmission modules, as well as a battery supply that lasts up to 8 hours. The indwelling camera takes images at a rate of 2 frames per second as peristalsis carries the capsule through the gastrointestinal tract. The average transit time from ingestion to evacuation is 24 hours. The device uses wireless radio transmission to send the images to a receiving recorder device that the patient wears around the waist. This receiving device also contains localizing antennae sensors that can roughly gauge where the image was taken over the abdomen. Images are then downloaded onto a workstation for viewing and processing.

Capsule endoscopy has been proposed as a method for identifying Crohn disease. There is no single criterion standard diagnostic test for Crohn disease; rather, diagnosis is based on a constellation of findings.\(^1\) Thus it is difficult to determine the diagnostic characteristics of various tests used to diagnose the condition and difficult to determine a single comparator diagnostic test to CE.

**Magnetic Capsule Endoscopy**

The U.S. Food and Drug Administration (FDA) approved a novel magnetically maneuvered CE system (NaviCam™; AnX Robotica, Inc.) in May 2020.\(^2\) This system consists of a single-use ingestible capsule and magnet linked to a physician-operated console. The capsule contains a camera that wirelessly captures images of the desired anatomy. The console allows the operator to control the motion and direction of the capsule, ensuring visualization of the entire stomach. The system is non-invasive, does not require sedation, and has a procedural time of approximately 15 to 20 minutes. The capsule leaves the body in 24 hours on average but may take as long as 2 weeks. The device is
contraindicated for use in patients with gastrointestinal obstruction, stenosis, fistula, or those with dysphagia. Other contraindications include patients with cardiac pacemakers or other implantable electronic medical devices as well as pregnant women, those <22 years of age, and those with a body mass index ≥38.

**Literature Review**
Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual); Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

**Suspected Small Bowel Bleeding**
**Clinical Context and Test Purpose**
The purpose of wireless capsule endoscopy (CE) for patients who have suspected small bowel bleeding is to confirm a diagnosis and inform a decision to proceed to appropriate treatment. The following PICO was used to select literature to inform this review.

**Populations**
The relevant population of interest is patients with suspected small bowel bleeding. Suspected small bowel bleeding, previously referred to as obscure gastrointestinal (GI) tract bleeding, is defined as bleeding from the GI tract that persists or recurs without an obvious etiology after imaging with upper and lower endoscopy and radiologic evaluation of the small bowel. Recurrent or persistent iron-deficiency anemia, positive fecal occult blood test, or visible bleeding with no bleeding source found at original endoscopy are other indicators of obscure GI tract bleeding. Examples of etiologies for small bowel bleeding include angiodysplasia, tumor, medication-induced, infections, Crohn disease (CD), Meckel diverticulum, Zollinger–Ellison syndrome, vasculitis, radiation enteritis, jejunal diverticula, and chronic mesenteric ischemia.

**Interventions**
The intervention of interest is wireless CE.

**Comparators**
The following practice is currently being used to diagnose small bowel bleeding: a standard workup without wireless CE and, with or without direct endoscopic procedures or specialized GI imaging. A “true” reference standard for suspected small bowel bleeding is difficult or impossible to achieve because the bleeding source may resolve, and invasive techniques (e.g., surgery) cannot be justifiably used.
Outcomes
The outcomes of interest for diagnostic accuracy include test validity (ie, sensitivity, specificity). The primary outcomes of interest are symptoms and disease status that would change due to patient management decisions following wireless CE.

Wireless CE would be performed prior to surgical exploration if conventional endoscopy has been inconclusive. Follow-up for further diagnostic evaluation and surveillance for recurrence of symptoms would be immediate to weeks if no etiology is identified. Follow-up of weeks to months would be based on the disease condition identified by CE.

Study Selection Criteria
Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
Systematic Reviews
Tables 2 and 3 summarize the characteristics and results of selected systematic reviews, which have evaluated a number of case series that compared the diagnostic accuracy of CE with alternative procedures such as intraoperative endoscopy or mesenteric angiography.

### Table 2. Characteristics of Systematic Reviews Evaluating Capsule Endoscopy for Iron-Deficient Anemia

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants</th>
<th>N (Range)</th>
<th>Design</th>
<th>QUADAS Assessment of Included Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koulaouzidis et al (2012)</td>
<td>2004-2011</td>
<td>24</td>
<td>Patients with iron-deficiency anemia who had SBCE and at least 1 lower and upper GI endoscopy prior to CE</td>
<td>1960 (35 to 652)</td>
<td>Observational</td>
<td>Low-to-moderate quality</td>
</tr>
</tbody>
</table>

CE: capsule endoscopy; GI: gastrointestinal; QUADAS: Quality Assessment of Diagnostic Accuracy Studies; SBCE: small bowel capsule endoscopy.

### Table 3. Results of Systematic Reviews Evaluating Capsule Endoscopy for Iron-Deficient Anemia

<table>
<thead>
<tr>
<th>Study</th>
<th>Overall Diagnostic Yielda</th>
<th>Diagnostic Yield of Patients With IDAb</th>
<th>P, %</th>
<th>Diagnostic Yield, n (%)c</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koulaouzidis et al (2012)</td>
<td>1960</td>
<td>264</td>
<td>9.4</td>
<td>293 (45.9)</td>
</tr>
<tr>
<td>Total N</td>
<td>1960</td>
<td>264</td>
<td>9.4</td>
<td>293 (45.9)</td>
</tr>
</tbody>
</table>

- Angioectasias: 293 (45.9)
- Inflammatory lesions: 126 (19.7)
- Polyp/mass lesions: 42 (6.6)
- Not classified: 177 (27.7)
Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders

Study Overall Diagnostic Yield, % Diagnostic Yield of Patients With IDA, % Diagnostic Yield, n (%)<sup>c</sup>
Pooled effect (95% CI), % 47 (42 to 52) 66.6 (61.0 to 72.3) 78.8 <0.001

CI: confidence interval; IDA: iron-deficient anemia; SBCE: small bowel capsule endoscopy.
<sup>a</sup> Per-patient analysis.
<sup>b</sup> From 4 studies (n=264 patients; 13.47% of total).
<sup>c</sup> Patients with positive SBCE findings.

Randomized Controlled Trials
A small randomized controlled trial (RCT) compared CE with mesenteric angiography in patients with acute melena or hematochezia. While CE had a higher diagnostic yield, secondary outcomes such as transfusion, hospitalization, and mortality did not differ significantly between groups. Tables 4 and 5 summarize the characteristics and results of selected RCTs.

Table 4. Characteristics of RCT Evaluating Capsule Endoscopy for Obscure GI Bleeding

<table>
<thead>
<tr>
<th>Study</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leung et al (2012)&lt;sup&gt;6&lt;/sup&gt;</td>
<td>China</td>
<td>1</td>
<td>2005-2007</td>
<td>Consecutive adults with active overt obscure GI bleeding</td>
<td>30 randomized to CE</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 randomized to angiography</td>
</tr>
</tbody>
</table>

CE: capsule endoscopy; GI: gastrointestinal; RCT: randomized controlled trial.

Table 5. Results of RCT Evaluating Capsule Endoscopy for Obscure GI Bleeding

<table>
<thead>
<tr>
<th>Study</th>
<th>Diagnostic Yield (95% CI), %&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Rebleeding Rates (95% CI), %</th>
<th>Hospitalization Rate, n (%)</th>
<th>Transfusion Rate, n (%)</th>
<th>Mean Follow-Up (SD), mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>CE</td>
<td>53.3 (36.1 to 69.8)</td>
<td>16.7 (7.3 to 33.6)</td>
<td>5 (16.7)</td>
<td>3 (10)</td>
<td>48.5 (20.9)</td>
</tr>
<tr>
<td>Angiography</td>
<td>20 (9.5 to 37.3)</td>
<td>33.3 (19.2 to 51.2)</td>
<td>5 (16.7)</td>
<td>3 (10)</td>
<td></td>
</tr>
<tr>
<td>Difference</td>
<td>33.3 (8.9 to 52.8)</td>
<td>16.7 (-5.3 to 36.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;sup&gt;p&lt;/sup&gt;</td>
<td>0.016</td>
<td>0.25</td>
<td>1.0</td>
<td>1.0</td>
<td></td>
</tr>
</tbody>
</table>

CI: confidence interval; CE: capsule endoscopy; GI: gastrointestinal; RCT: randomized controlled trial; SD: standard deviation.
<sup>a</sup> Percentage identified with a high probability of bleeding.

The purpose of the limitations tables (Tables 6 and 7) is to display notable limitations identified in each study. This information is synthesized as a summary of the body of evidence following each table and provides the conclusions on the sufficiency of the evidence supporting the position statement.

Table 6. Study Relevance Limitations of RCT Evaluating Capsule Endoscopy for Obscure GI Bleeding

<table>
<thead>
<tr>
<th>Study</th>
<th>Population&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Intervention&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Comparator&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Outcomes&lt;sup&gt;d&lt;/sup&gt;</th>
<th>Duration of Follow-Up&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leung et al (2012)&lt;sup&gt;6&lt;/sup&gt;</td>
<td>2. It is possible patients with moderate bleeding would not undergo angiography in a clinical setting</td>
<td>2. A criterion standard is lacking for evaluation of obscure GI bleeding</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4. Patients with overt but nonmassive bleeding may not be ideal for CE or angiography</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CE: capsule endoscopy; GI: gastrointestinal; RCT: randomized controlled trial.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.
<sup>a</sup> Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.
<sup>b</sup> Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.
<sup>c</sup> Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.
Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity, and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconveniences of venipuncture or noninvasive tests).

Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true-positives, true-negatives, false-positives, false-negatives cannot be determined).

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation</th>
<th>Blinding</th>
<th>Selective Reporting</th>
<th>Follow-Up</th>
<th>Power</th>
<th>Statistical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leung et al (2012)⁶</td>
<td></td>
<td></td>
<td></td>
<td>3. Study underpowered to detect significant difference in clinical outcome</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GI: gastrointestinal; RCT: randomized controlled trial.
The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.


Follow-Up key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

Statistical key: 1. Intervention is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Intervention is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Case Series
Tables 8 and 9 summarize the characteristics and results of selected case series.

Table 8. Characteristics of Case Series Evaluating Capsule Endoscopy for Obscure GI Bleeding

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Participants</th>
<th>Treatment Delivery</th>
<th>Follow-Up (Range), mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hartmann et al (2005)⁷</td>
<td>Germany</td>
<td>47 patients &gt;18 y with obscure GI bleeding</td>
<td>Patients received CE and intraoperative endoscopy</td>
<td>NR</td>
</tr>
<tr>
<td>Pennazio et al (2004)⁸</td>
<td>Italy</td>
<td>100 patients ≥18 y with obscure GI bleeding</td>
<td>51 patients received CE and PE before or after the procedure</td>
<td>Mean: 18 (5 to 25)</td>
</tr>
</tbody>
</table>

CE: capsule endoscopy; GI: gastrointestinal; NR: not reported; PE: push enteroscopy.

Table 9. Results of Case Series Evaluating Capsule Endoscopy for Obscure GI Bleeding

<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment</th>
<th>Locating Bleeding With CE, % Sensitivity</th>
<th>Locating Bleeding With CE, % Specificity</th>
<th>Diagnostic Yield for Positive Lesions, %</th>
<th>PPV of CE, %</th>
<th>NPV of CE, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hartmann et al (2005)⁷</td>
<td>CE and intraoperative endoscopy</td>
<td>95</td>
<td>75</td>
<td>Both procedures: 76.6</td>
<td>95</td>
<td>86</td>
</tr>
<tr>
<td>Pennazio (2004)⁸</td>
<td>CE and PE</td>
<td>89</td>
<td>95</td>
<td>67 (95% CI, 54 to 80)</td>
<td>97</td>
<td>82.6</td>
</tr>
</tbody>
</table>

CE: capsule endoscopy; CI: confidence interval; GI: gastrointestinal; NPV: negative predictive value; PE: push enteroscopy; PPV: positive predictive value.

⁶ CE results confirmed by intraoperative endoscopy or other reference standards.
Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Based on evidence that CE isolates the source of bleeding at least as well as other diagnostic tools and that few diagnostic options are available to patients with suspected small bowel bleeding, a chain of evidence can be constructed to support the clinical utility of CE for this indication.

Section Summary: Suspected Small Bowel Bleeding
A small RCT compared CE with mesenteric angiography in patients with acute melena or hematochezia. While CE had a higher diagnostic yield, secondary outcomes such as transfusion, hospitalization, and mortality did not differ significantly between groups. A large number of uncontrolled studies have evaluated the use of CE in the evaluation of patients with suspected small bowel bleeding. These studies have consistently reported that a substantial proportion of patients receive a definitive diagnosis following this test when there are few other diagnostic options. A meta-analysis of 24 studies estimated that the diagnostic yield in this patient population was approximately half of the included patients and was higher in patients with documented iron-deficiency anemia. Capsule endoscopy appears to locate the source of bleeding at least as well as other diagnostic methods and direct treatment to the source of bleeding.

Suspected Crohn Disease
Clinical Context and Test Purpose
The purpose of wireless CE for patients with suspected CD is to confirm a diagnosis and inform a decision to proceed to appropriate treatment.

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is individuals with suspected CD. Crohn disease is 1 of the 2 types of inflammatory bowel disease. Crohn disease can involve the entire GI tract and is characterized by transmural inflammation.

Interventions
The test being considered is wireless CE.

Comparators
The following tests are currently being used to diagnose CD: ileocolonoscopy, barium small bowel follow-through, computed tomography enterography (CTE), and magnetic resonance enterography (MRE).

Outcomes
The general outcomes of interest are test validity, other test performance measures, symptoms, and change in disease status.
The diagnosis of CD requires confirmatory imaging when the disease is prominent on the differential diagnosis list. The imaging study would be performed and promptly followed by appropriate treatment. Crohn disease is a chronic condition requiring long-term follow-up.

**Study Selection Criteria**

Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

**Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

**Review of Evidence**

**Systematic Reviews**

Results from a meta-analysis by Choi et al (2017), which compared CE with various modalities for diagnosing CD, are summarized in Tables 10 and 11. The reference standards varied for the selected studies, so quantitative data were not synthesized for diagnostic accuracy. In the pooled analysis, in patients with suspected CD, the sensitivity of CE ranged from 89.6% to 92.0% and the specificity was 100%.

**Table 10. Characteristics of Systematic Reviews Assessing the Diagnostic Yield of Capsule Endoscopy versus Other Modalities**

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants</th>
<th>N (Range)</th>
<th>Design</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choi et al (2017)</td>
<td>2002-2013</td>
<td>24</td>
<td>Patients with suspected or established CD</td>
<td>NR</td>
<td>RCT, nonrandomized, and diagnostic accuracy studies</td>
</tr>
</tbody>
</table>

CD: Crohn disease; NR: not reported; RCT: randomized controlled trial.

*Other modalities include small bowel follow-through, enteroclysis, computed tomography enterography, and magnetic resonance enterography.

**Table 11. Results of Systematic Reviews Assessing the Diagnostic Yield of Capsule Endoscopy versus Other Modalities**

<table>
<thead>
<tr>
<th>Study</th>
<th>CE vs. SBFT*</th>
<th>CE vs. EC*</th>
<th>CE vs. CTE*</th>
<th>CE vs. MRE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choi et al (2017)*</td>
<td>66 vs. 21.3</td>
<td>75.7 vs. 29.4</td>
<td>72.5 vs. 22.5</td>
<td>85.7 vs. 100</td>
</tr>
<tr>
<td>Diagnostic yield, %</td>
<td>0.44 (0.29 to 0.59)</td>
<td>0.50 (0.21 to 0.79)</td>
<td>0.36 (0.18 to 0.90)</td>
<td>-0.16 (-0.63 to 0.32)</td>
</tr>
</tbody>
</table>

*From 4 studies (3 included in meta-analysis).

**Table 11. Results of Systematic Reviews Assessing the Diagnostic Yield of Capsule Endoscopy versus Other Modalities**

<table>
<thead>
<tr>
<th>Study</th>
<th>CE vs. SBFT*</th>
<th>CE vs. EC*</th>
<th>CE vs. CTE*</th>
<th>CE vs. MRE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choi et al (2017)*</td>
<td>66 vs. 21.3</td>
<td>75.7 vs. 29.4</td>
<td>72.5 vs. 22.5</td>
<td>85.7 vs. 100</td>
</tr>
<tr>
<td>Diagnostic yield, %</td>
<td>0.44 (0.29 to 0.59)</td>
<td>0.50 (0.21 to 0.79)</td>
<td>0.36 (0.18 to 0.90)</td>
<td>-0.16 (-0.63 to 0.32)</td>
</tr>
</tbody>
</table>

CE: capsule endoscopy; CI: confidence interval; CTE: computed tomography enterography; EC: enteroclysis; MRE: magnetic resonance enterography; SBFT: small bowel follow-through.

*From 4 studies (3 included in meta-analysis).

*From 2 studies.
Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of wireless CE for this indication were identified.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Based on evidence that CE can provide a diagnosis of CD when other tests cannot, a chain of evidence can be constructed to support the clinical utility of CE for this indication.

Section Summary: Suspected Crohn Disease
For patients with suspected CD who cannot be diagnosed by other modalities, CE can confirm the diagnosis in a substantial number of patients.

Suspected Celiac Disease
Clinical Context and Test Purpose
The purpose of wireless CE for patients who have suspected celiac disease is to confirm a diagnosis and inform a decision to proceed to appropriate treatment.

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is individuals with suspected celiac disease. Celiac disease, or gluten-sensitive enteropathy, is an immune-mediated condition of the small intestine. Serologic markers of the disease have good sensitivity and specificity in triaging patients to endoscopy.

Interventions
The test being considered is wireless CE. Capsule endoscopy has been evaluated as an alternative method of diagnosing celiac disease, assessing the extent of disease, and in the evaluation of celiac disease unresponsive to treatment.

Comparators
The following test is currently being used to diagnose celiac disease: endoscopy with biopsy. The criterion standard for the diagnosis of celiac disease is obtained through small bowel biopsies during endoscopy.

Outcomes
The general outcomes of interest are test validity, other test performance measures, symptoms, and change in disease status.

The diagnosis of celiac disease requires confirmatory imaging when the disease is prominent on the differential diagnosis list. The imaging study would be performed and promptly followed by appropriate treatment. Celiac disease is a chronic condition requiring long-term follow-up.
Study Selection Criteria
Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
Systematic Reviews
A meta-analysis by El-Matary et al (2009) compared the diagnostic performance of CE with a reference standard of duodenal biopsy. The pooled analysis of 3 studies showed a sensitivity of 83% and a specificity of 98%. Another meta-analysis by Rokkas and Niv (2012) also compared the diagnostic performance of CE with biopsy, summarizing 6 studies (N=166 subjects). The overall pooled sensitivity was 89%, and the specificity was 95%.

Capsule endoscopy detected involvement of intestines beyond the duodenum; however, the clinical significance of detecting the extent of celiac disease is uncertain. Given the less than 90% sensitivity of CE for celiac disease, it does not appear to be an adequate alternative method of making an initial diagnosis.

Nonrandomized Studies
In a study by Kurien et al (2013), 62 patients with an equivocal diagnosis of celiac disease and 69 patients with confirmed celiac disease who were unresponsive to standard treatment were evaluated with CE. Results were combined with human leukocyte antigen typing and response to gluten challenge, with the final diagnosis made by 3 expert physicians who received the information from all 3 sources. The main outcome was the increase in diagnostic yield after CE combined with the other tests. The diagnostic yield was greatest in cases with antibody-negative villous atrophy where a diagnosis of celiac disease was made in 9 (28%) of 32 patients. In 8 (12%) of the 69 nonresponsive celiac disease patients, CE identified 2 cases of enteropathy-associated lymphoma, 4 type 1 refractory disease cases, 1 fibroepithelial polyp, and 1 case of ulcerative jejunitis. This study was limited by the small sample size and use of other tests in conjunction with CE to ascertain a final diagnosis.

One case series by Culliford et al (2005) evaluated 47 patients with complicated celiac disease and found unexpected additional findings in 60% of patients, most of which were ulcerations. However, the definition of “complicated” celiac disease included other factors such as evidence of blood loss, itself an indication for CE. The impact on patient management and outcomes is unclear.

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.
**Direct Evidence**
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of wireless CE for this indication were identified.

**Chain of Evidence**
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of wireless CE for diagnosing celiac disease has not been established, a chain of evidence supporting the test’s clinical utility for this indication cannot be constructed.

**Section Summary: Suspected Celiac Disease**
In cases where the diagnosis of celiac disease is equivocal, CE can sometimes reveal morphologic changes in the small bowel consistent with celiac disease. However, it is unlikely that the appearance of small bowel on CE is itself sufficient to make a definitive diagnosis of celiac disease. Small bowel biopsy, celiac serologies, and human leukocyte antigen typing remain the standard tests for confirming celiac disease and have a higher sensitivity and specificity for this purpose. Case series of patients with unresponsive celiac disease undergoing CE have shown some yield of actionable diagnoses that have the potential to improve patient outcomes. Larger studies are needed to better determine the diagnostic yield of CE in these patients.

**Unexplained Chronic Abdominal Pain**

**Clinical Context and Test Purpose**
The purpose of wireless CE for patients who have unexplained chronic abdominal pain is to confirm a diagnosis and inform a decision to proceed to appropriate treatment.

The following PICO was used to select literature to inform this review.

**Populations**
The relevant population of interest is individuals with unexplained chronic abdominal pain.

**Interventions**
The test being considered is wireless CE.

**Comparators**
The following practice is currently being used to diagnose chronic abdominal pain: standard workup for abdominal pain without CE.

**Outcomes**
The general outcomes of interest are test validity, other test performance measures, symptoms, and change in disease status.

The diagnosis of chronic abdominal pain is often one of exclusion after a comprehensive clinical evaluation including empirical treatment. Imaging studies are used during initial and follow-up evaluations. Continued follow-up would be based on a definitive or working diagnosis, which would typically occur over weeks to months.

**Study Selection Criteria**
Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
Systematic Reviews
Xue et al (2015) reported on a systematic review of 21 studies (N=1520 patients) evaluating CE for unexplained chronic abdominal pain. The pooled diagnostic yield was 20.9% (95% confidence interval [CI], 15.9% to 25.9%). The most commonly identified findings were inflammatory lesions (78.3%) and tumors (9.0%). Studies in the review were highly heterogeneous. Limitations in interpreting the findings included retrospective study designs, different durations of abdominal pain, and the use of different tests before CE.

Case Series
In a study not included in the systematic review, Yang et al (2014) reported on a case series evaluating 243 patients with CE for unexplained chronic abdominal pain. The diagnostic yield of CE was 23.0%. Identified findings included 19 (7.8%) patients with CD, 15 (6.2%) with enteritis, 11 (4.5%) with idiopathic intestinal lymphangiectasia, 5 (2.1%) with uncinariasis, and 5 (2.1%) with abnormal transit time and other findings (e.g., small bowel tumor, ascariasis, anaphylactoid purpura).

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of wireless CE for this indication were identified.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of wireless CE for diagnosing unexplained chronic abdominal pain has not been established, a chain of evidence supporting the test’s clinical utility for this indication cannot be constructed.

Section Summary: Unexplained Chronic Abdominal Pain
While CE diagnosed unexplained chronic abdominal pain in a proportion of patients reported in retrospective studies, the sequence and chronology of testing and treatment recommended before CE needs to be defined to determine whether CE has utility to diagnose the condition.
Established Crohn Disease
Clinical Context and Test Purpose
The purpose of wireless CE for patients who have an established diagnosis of CD is to inform management decisions based on disease status.

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is patients with CD.

Interventions
The intervention of interest is wireless CE.

Comparators
The following tests are currently being used to monitor CD: ileocolonoscopy, barium small bowel follow-through, CTE, and MRE.

Outcomes
The beneficial outcome of a true test result, if correctly classified as low disease activity, is the avoidance of endoscopy and unnecessary medications.

Wireless CE would be performed to monitor patients with CD.

Study Selection Criteria
Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
Systematic Reviews
Kopylov et al (2017) published a systematic review of studies evaluating the use of CE for CD.\textsuperscript{16} Reviewers included prospective studies comparing CE with MRE and/or small bowel contrast ultrasound in patients who had suspected and/or established CD. In pooled analyses of the 11 studies that included patients with established CD, the diagnostic yield of CE was similar to that of MRE (odds ratio [OR], 1.88; 95% CI, 0.53 to 1.48; $\hat{\pi} = 48\%$) and to ultrasound (OR, 0.57; 95% CI, 0.27 to 1.20; $\hat{\pi} = 67\%$).

Diagnostic Accuracy Studies
Bruining et al (2020) reported results from the multicenter, prospective BLINK trial comparing the diagnostic accuracy of CE compared to ileocolonoscopy and/or MRE in patients with established CD.\textsuperscript{17} The per-protocol analysis included 99/158 enrolled subjects with 16 patients tested by all 3
modalities. Major reasons for exclusion from analysis included patency failure or MRE stricture and major protocol violations. The reference standard was defined as the presence or absence of inflammation as designated by the modality-specific scoring system at prospective interpretation by expert central readers. In cases of discrepant findings for any bowel segment, all modalities were reviewed and resolved by a consensus panel consisting of 3 gastroenterologists. Overall sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 94% (95% CI, 86% to 98%), 74% (95% CI, 55% to 87%), 91% (95% CI, 82% to 96%), and 83% (95% CI, 64% to 94%) for CE compared to 100% (95% CI, 95% to 100%), 22% (95% CI, 10% to 41%), 77% (95% CI, 68% to 85%), and 100% (95% CI, 54% to 100%) for ileocolonoscopy and/or MRE. Sensitivity of CE was significantly higher compared to MRE for enteric inflammation in the proximal small bowel (97% vs. 71%, p=.021) and similar in the terminal ileum and colon (p=.500 to.625). Discrepant reads between the proximal small bowel, terminal ileum, and colon were 57%, 49%, and 81%, respectively. In the proximal small bowel, the majority consensus panel decision was agreement with CE.

Cohort Studies
A study by Elosua et al (2022) evaluated the therapeutic impact of CE in patients with established CD in this retrospective, single-center study.18 Therapeutic impact was defined as change in CD-related treatment recommended based on CE results and 305 patients (N=432 procedures) with established CD who underwent a CE procedure between January 2008 and December 2019 were included. Of the included CE procedures, 87.5% were deemed conclusive. Mild inflammation was detected in 41.6% of patients and moderate-to-severe activity was detected in 21.9% of patients. Management changes guided by CE procedures occurred in 51.3% of procedures, with 46.1% of procedures leading to treatment escalation and 5.3% of procedures leading to de-escalation. Disease activity demonstrated by CE results was correlated with therapeutic changes. Mucosal healing assessed via CE was the only independent factor that predicted therapy de-escalation (OR, 6.86; 95% CI, 1.42 to 33). The single-center group of clinicians limited heterogeneity. These results are limited by the retrospective design of the study.

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of wireless CE for this indication were identified.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Based on evidence that CE has a similar diagnostic yield as radiography when used to monitor CD and CE can be used when radiography cannot, a chain of evidence can be constructed to support the clinical utility of CE for this indication.

Section Summary: Established Crohn Disease
A 2017 systematic review of 11 studies in patients with established CD found a similar diagnostic yield with CE compared with radiography. A diagnostic accuracy study of CE compared with ileocolonoscopy and/or MRE for the detection of active inflammatory CD in patients with established CD found a comparable sensitivity, higher specificity and PPV, and lower NPV compared to ileocolonoscopy and/or MRE. Differences may be attributed to high rates of discrepant reads
between modalities, and high consensus panel agreement with CE results in cases of discrepancy. A retrospective cohort study demonstrated therapeutic management changes based on CE results, but RCTs are still needed to further assess the impact of CE results on therapy management.

**Ulcerative Colitis**

**Clinical Context and Test Purpose**
The purpose of wireless CE for patients who have ulcerative colitis is to inform management decisions based on disease status.

The following PICO was used to select literature to inform this review.

**Populations**
The relevant population of interest is individuals with ulcerative colitis.

**Interventions**
The test being considered is wireless CE.

**Comparators**
The following test is currently being used to manage ulcerative colitis: optical colonoscopy.

**Outcomes**
The general outcomes of interest are test validity, other test performance measures, symptoms, and change in disease status.

Wireless CE would be performed to monitor patients after a confirmed diagnosis of ulcerative colitis.

**Study Selection Criteria**
Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

**Clinically Valid**
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

**Review of Evidence**
A number of prospective observational studies have evaluated the diagnostic accuracy of CE in patients with ulcerative colitis. Tables 12 and 13 summarize the characteristics and results of these studies.
Table 12. Characteristics of Observational Comparative Studies Assessing CE for UC

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Type</th>
<th>Country</th>
<th>Dates</th>
<th>Participants</th>
<th>Treatment</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shi et al (2017)(^19)</td>
<td>Single-center</td>
<td>China</td>
<td>2014-2016</td>
<td>Patients 18 to 80 y with UC requiring colonoscopy</td>
<td>150 patients underwent CE-2 and colonoscopy</td>
<td>NR</td>
</tr>
<tr>
<td>San Juan-Acosta et al (2014)(^20)</td>
<td>Single-blind comparative</td>
<td>Spain</td>
<td>2010-2012</td>
<td>Patients 18 to 70 y with UC in disease activity or due for CRC screening</td>
<td>23 underwent CE-1, 19 had CE-2; all followed by colonoscopy</td>
<td>NR</td>
</tr>
<tr>
<td>Oliva et al (2014)(^21)</td>
<td>Prospective observational</td>
<td>Spain</td>
<td>2011-2012</td>
<td>Patients 6 to 18 y with a diagnosis at least 3 mo prior to enrollment</td>
<td>30 patients underwent CE-2, followed by colonoscopy</td>
<td>NR</td>
</tr>
<tr>
<td>Sung et al (2012)(^22)</td>
<td>Prospective cohort</td>
<td>China and Singapore</td>
<td>2000-2008</td>
<td>Patients with suspected or known UC</td>
<td>100 patients underwent CE and same-day colonoscopy</td>
<td>NR</td>
</tr>
</tbody>
</table>

CE-1: first-generation capsule endoscopy; CE-2: second-generation capsule endoscopy; CRC: colorectal cancer; NR: not reported; UC: ulcerative colitis.

Table 13. Results of Observational Comparative Studies Assessing CE for Ulcerative Colitis

<table>
<thead>
<tr>
<th>Study</th>
<th>Active Colonic Inflammation, %</th>
<th>PPV, %</th>
<th>NPV, %</th>
<th>Correlation Between Colon CE and Colonoscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity(^a)</td>
<td>Specificity</td>
<td></td>
<td>Disease Severity</td>
</tr>
<tr>
<td>Shi et al (2017)(^19)</td>
<td>N</td>
<td>150</td>
<td>150</td>
<td>150</td>
</tr>
<tr>
<td>Mucosal inflammation (MES &gt;0)</td>
<td>97</td>
<td>94 to 95</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M-to-S inflammation (MES &gt;1)</td>
<td>94</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postinflammatory polyps</td>
<td>100</td>
<td>91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICC (95% CI)</td>
<td>0.69 (0.46 to 0.81)</td>
<td>0.64 (0.38 to 0.78)</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

San Juan-Acosta et al (2014)\(^20\):

| N | 42 | 42 | 42 | 42 |
| CE vs colonoscopy | Disease activity | 77.78 | 95.83 | 93.33 | 85.19 |
| Disease extent | 68.75 | 96.15 | 91.67 | 83.33 |
| ICC (95% CI) | 0.79 (0.62 to 0.96) | 0.71 (0.52 to 0.90) |

Oliva et al (2014)\(^21\):

| N | 30 | 30 | 30 |
| % (95% CI) | 96 (79 to 99) | 100 (61 to 100) | 100 (85 to 94 to 97) |

Sung et al (2012)\(^22\):

| N | 100 | 100 | 100 |
| % (95% CI) | 89 (80 to 95) | 75 (51 to 90) | 93 (84 to 97) |

CE: capsule endoscopy; CI: confidence interval; ICC: intraclass correlation coefficient; MES: Mayo Endoscopic Subscore; M-to-S: moderate to severe; NPV: negative predictive value; PPV: positive predictive value.

\(^a\) MES.

\(^b\) Ulcerative Colitis Endoscopic Index of Severity.

In the study by San Juan-Acosta et al (2014), although the correspondence between the 2 methods was reasonably good, it is uncertain whether management changes based on 1 or the other test would result in similar or different patient outcomes.\(^20\).
Oliva et al (2014) evaluated 30 patients with known ulcerative colitis with both CE and colonoscopy to assess disease activity. The reference standard for disease activity was a Matts score greater than 6 as judged by colonoscopy. Although the 2 methods had a high concordance at this cutoff level of disease in this study, patient outcomes linked to these assessments of disease activity cannot be determined.

**Clinically Useful**
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

**Direct Evidence**
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of wireless CE for this indication were identified.

**Chain of Evidence**
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of wireless CE for monitoring ulcerative colitis has not been established, a chain of evidence supporting the test’s clinical utility for this indication cannot be constructed.

**Section Summary: Ulcerative Colitis**
Several diagnostic accuracy studies have compared CE with colonoscopy to assess disease activity in patients with ulcerative colitis. Two of 4 studies were small (i.e., <50 patients) and thus data on diagnostic accuracy are limited. Because there are insufficient data on diagnostic accuracy, a chain of evidence on clinical utility cannot be constructed.

**Esophageal Disorders**

**Clinical Context and Test Purpose**
The purpose of wireless CE for patients who have esophageal disorders is to inform management decisions based on disease status.

The following PICO was used to select literature to inform this review.

**Populations**
The relevant population of interest is individuals with esophageal disorders. Gastroesophageal reflux disease and chronic sequelae such as Barrett esophagus may require diagnostic and surveillance interventions.

**Interventions**
The test being considered is wireless CE. In the esophagus, the capsule camera has been proposed as a screening technique for Barrett esophagus associated with gastroesophageal reflux disease. Evaluation of the esophagus requires limited transit time, and it is estimated that the test takes 20 minutes to perform.

Capsule endoscopy can visualize several types of esophageal conditions. It could substitute for traditional upper endoscopy for several indications and may have the advantage of comfort and convenience. However, interventional procedures and biopsies cannot be performed with CE. Capsule endoscopy could triage patients for endoscopy if either the sensitivity or the specificity is high. Traditional endoscopy could then be performed on the appropriate group to determine false-
positives or false-negatives, having spared the group with a high positive predictive value an endoscopy procedure.

**Comparators**
The following test is currently being used to manage esophageal disorders: upper GI endoscopy.

**Outcomes**
The general outcomes of interest are test validity, other test performance measures, symptoms, and change in disease status.

Wireless CE would be performed to monitor patients after a confirmed diagnosis of an esophageal disorder.

**Study Selection Criteria**
Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

**Clinically Valid**
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

**Review of Evidence**

**Systematic Reviews**
Most studies have shown that CE has inferior diagnostic characteristics compared with traditional upper endoscopy for a variety of esophageal conditions. A meta-analysis by Guturu et al (2011) evaluated 9 studies comparing CE with traditional endoscopy for detecting esophageal varices and calculated a sensitivity of 83% and specificity of 85%.23 A meta-analysis by Bhardwaj et al (2009) assessed 9 studies comparing CE with traditional endoscopy for detecting Barrett esophagus and reported a sensitivity of 77% and specificity of 86%.24 Because of the lower sensitivity and specificity of that test, CE cannot substitute for traditional endoscopy nor can it be used to triage patients to endoscopy.

**Clinically Useful**
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

**Direct Evidence**
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of wireless CE for this indication were identified.
Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility. Because the clinical validity of wireless CE for monitoring esophageal disorders has not been established, a chain of evidence supporting the test’s clinical utility for this indication cannot be constructed.

Section Summary: Esophageal Disorders
Other available modalities are superior to CE for monitoring esophageal disorders. The diagnostic characteristics of CE are inadequate to substitute for other modalities or to triage patients to other modalities.

Hereditary Gastrointestinal Polyposis Syndromes

Clinical Context and Test Purpose
The purpose of wireless CE for patients who have hereditary GI polyposis syndromes is to inform management decisions based on disease status.

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is individuals with hereditary GI polyposis syndromes, including Lynch syndrome and Peutz-Jeghers syndrome (PJS).

Interventions
The test being considered is wireless CE.

Comparators
The following tests and practices are currently being used to manage hereditary GI polyposis syndromes: ileocolonoscopy, barium small bowel follow-through, CTE, and MRE.

Outcomes
The general outcomes of interest are, test validity, other test performance measures, symptoms, and change in disease status.

Wireless CE would be performed to monitor patients after a confirmed diagnosis with hereditary GI polyposis syndromes.

Study Selection Criteria
Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).
**Review of Evidence**
Persons with familial adenomatous polyposis and PJS are genetically at high-risk of small bowel polyps and tumors. Urquhart et al (2014) compared CE with MRE in 20 patients with PJS. Capsule endoscopy identified more polyps 10 mm or larger (47 polyps) than MRE (14 polyps; p=.02). However, subsequent balloon enteroscopy in 12 patients showed a poor correlation of findings between techniques, with a 100% PPV of finding a polyp on balloon enteroscopy with MRE versus 60% for CE. A study by Brown et al (2006) in 19 patients showed a greater number of polyps identified with CE than with barium follow-through examinations. Mata et al (2005) studied the role of CE in 24 patients with hereditary GI polyposis syndromes, including familial adenomatous polyposis (n=20) or PJS (n=4). Compared with barium studies using small bowel enteroclysis, CE identified 4 additional patients with small bowel polyps, which were subsequently removed with endoscopic polypectomy. Although these studies were small, they demonstrated that CE can identify additional lesions compared with other diagnostic methods in persons with disease syndromes at high-risk for such lesions.

The lifetime risk of small bowel cancer in Lynch syndrome has been estimated at 5%. Although not extremely high, this risk is greatly increased compared with the general population. There are a few case series of the prevalence of neoplastic lesions in asymptomatic patients with Lynch syndrome. Haanstra et al (2015) evaluated 200 patients with Lynch syndrome who underwent CE. Small bowel neoplasia was detected in the duodenum in 2 patients (1 adenocarcinoma, 1 adenoma). These lesions would have been in the reach of a gastroduodenoscope. In a smaller study by Saurin et al (2010), 35 asymptomatic patients with Lynch syndrome underwent colon CE. Small bowel neoplasms were diagnosed in 3 (8.6%) patients (1 adenocarcinoma, 2 adenomas with low-grade dysplasia).

**Clinically Useful**
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

**Direct Evidence**
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of wireless CE for this indication were identified.

**Chain of Evidence**
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility. Because the clinical validity of wireless CE for monitoring hereditary GI polyposis syndromes has not been established, a chain of evidence supporting the test’s clinical utility for this indication cannot be constructed.

**Section Summary: Hereditary Gastrointestinal Polyposis Syndromes**
Although studies have shown at least a low prevalence of small bowel neoplasms, these data are insufficient to determine whether evaluation with CE would improve patient outcomes. Additional data on the prevalence and natural history of small bowel polyps in Lynch syndrome patients are necessary. At this time, surveillance of the small bowel is not generally recommended as a routine intervention for patients with Lynch syndrome.

**Portal Hypertensive Enteropathy**
**Clinical Context and Test Purpose**
The purpose of wireless CE for patients who have portal hypertensive enteropathy is to inform management decisions based on disease status.
The following PICO was used to select literature to inform this review.

**Populations**
The relevant population of interest is individuals with portal hypertensive enteropathy.

**Interventions**
The test being considered is wireless CE.

**Comparators**
The following test is currently being used to manage portal hypertensive enteropathy: upper and lower endoscopy.

**Outcomes.**
The general outcomes of interest are test validity, other test performance measures, symptoms, and change in disease status.

Wireless CE would be performed to monitor patients after a confirmed diagnosis with portal hypertensive enteropathy.

**Study Selection Criteria**
Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

**Clinically Valid**
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

**Review of Evidence**
**Systematic Reviews**
Several systematic reviews, including a Cochrane review, have been published. Tables 14 and 15 summarize the characteristics and results of select systematic reviews.

**Table 14. Characteristics of Systematic Reviews Assessing Capsule Endoscopy for Portal Hypertensive Enteropathy**

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Trials</th>
<th>Participants</th>
<th>N (Range)</th>
<th>Design</th>
</tr>
</thead>
</table>

NR: not reported.

**Table 15. Results of Systematic Reviews Assessing Capsule Endoscopy for Portal Hypertensive Enteropathy**

<table>
<thead>
<tr>
<th>Study</th>
<th>CE, %</th>
<th>Likelihood Ratios</th>
<th>Diagnostic Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity</td>
<td>Specificity</td>
<td>Positive</td>
</tr>
</tbody>
</table>

Reproduction without authorization from Blue Shield of California is prohibited
Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders

<table>
<thead>
<tr>
<th>Study</th>
<th>CE, %</th>
<th>Likelihood Ratios</th>
<th>Diagnostic Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td>McCarty et al (2017)36</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>1328</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE (95% CI), %</td>
<td>(83 to 89)</td>
<td>(85 to 91)</td>
<td>(5.4 to 9.0)</td>
</tr>
<tr>
<td></td>
<td>0.20 (0.14 to 0.28)</td>
<td>90 (88 to 93)</td>
<td>92 (90 to 94)</td>
</tr>
<tr>
<td>Studies with low risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>of bias, n</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE (95% CI), %</td>
<td>(80 to 88)</td>
<td>(86 to 94)</td>
<td>(85 to 88)</td>
</tr>
<tr>
<td></td>
<td>92 (89 to 94)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colli et al (2014)31</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>936</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE (95% CI), %</td>
<td>(84.8 to 90.2)</td>
<td>(84.3 to 91.4)</td>
<td>(5.4 to 9.5)</td>
</tr>
<tr>
<td></td>
<td>0.18 (0.12 to 0.27)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Studies with low risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>of bias, n</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE (95% CI), %</td>
<td>(79.7 to 85.0)</td>
<td>(86.1 to 95.5)</td>
<td>(5.8 to 16.1)</td>
</tr>
<tr>
<td></td>
<td>0.24 (0.18 to 0.31)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CE: capsule endoscopy; CI: confidence interval; PE: pooled effect.

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of wireless CE for this indication were identified.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of wireless CE for monitoring portal hypertensive enteropathy has not been established, a chain of evidence supporting the test’s clinical utility for this indication cannot be constructed.

Section Summary: Portal Hypertensive Enteropathy
Capsule endoscopy has been used to diagnose portal hypertensive enteropathy. Systematic reviews of studies of its diagnostic performance have reported limited sensitivity and specificity. Because neither the sensitivity nor the specificity was high for identifying esophageal varices, CE should not be used instead of esophagogastroduodenoscopy nor should it be used to triage patients to esophagogastroduodenoscopy. Based on these diagnostic characteristics, the test does not appear to have clinical utility.

Acute Upper Gastrointestinal Tract Bleeding
Clinical Context and Test Purpose
The purpose of wireless CE for patients who have acute upper GI tract bleeding is to inform management decisions based on disease status.

The following PICO was used to select literature to inform this review.

**Populations**
The relevant population of interest is patients with acute upper GI tract bleeding.
Interventions
The intervention of interest is wireless CE.

Comparators
The following practices are currently being used to manage acute upper GI tract bleeding: standard workup of acute bleeding without wireless CE and, with or without direct endoscopic procedures or specialized GI imaging.

Outcomes
The primary outcomes of interest for clinical utility are symptoms and disease status that would change due to patient management decisions following wireless CE. Other outcomes of interest are the avoidance of hospitalizations and reductions in resource utilization (e.g., need for additional testing or procedures).

Wireless CE would be performed as soon as possible after acute bleeding is identified. Wireless CE would be performed to monitor patients after a confirmed diagnosis with acute GI tract bleeding.

Study Selection Criteria
Below are selection criteria for studies to assess whether a test is clinically valid.
- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
Randomized Controlled Trials
Sung et al (2016) reported on a prospective RCT to evaluate the use of CE in the emergency department for patients with suspected upper GI bleeding. Capsule endoscopy was used to determine whether patients would be admitted to the hospital or sent home, versus an alternative strategy of admitting all patients. Eligible patients presented with signs and/or symptoms of acute upper GI bleeding but were without hemodynamic shock or conditions likely to preclude the use of the capsule endoscope. Seventy-one patients were randomized to CE in the emergency department (n=37), followed by monitoring for upper GI bleeding, or standard care (n=34), which included mandatory hospital admission. Seven CE patients with active bleeding or endoscopic findings were admitted, with the remainder discharged home. There were no deaths or morbid outcomes in either group, indicating that CE could result in equivalent patient outcomes with many patients safely avoiding emergency hospitalization.

Tables 16 and 17 summarize the characteristics and results of select RCTs.
Table 16. Characteristics of RCTs Assessing Capsule Endoscopy for Acute Gastrointestinal Tract Bleeding

<table>
<thead>
<tr>
<th>Study</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
<th>Comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung et al (2016)</td>
<td>China</td>
<td>NR</td>
<td>2013-2014</td>
<td>Patients presenting to ED with symptoms suggestive of UGIB</td>
<td>Active 37 randomized to CE; admission determined by CE</td>
<td>34 randomized to SOC; admission determined by GBS</td>
</tr>
<tr>
<td>Gutkin et al (2013)</td>
<td>U.S.</td>
<td>3</td>
<td>NR</td>
<td>Patients ≥18 y with history suggestive of acute UGIB ≤48 h prior to ED presentation</td>
<td>12 randomized to VCE prior to endoscopy</td>
<td>12 randomized to endoscopy</td>
</tr>
</tbody>
</table>

CE: capsule endoscopy; ED: emergency department; GBS: Glasgow Blatchford score; NR: not reported; RCT: randomized controlled trial; SOC: standard of care; UGIB: upper gastrointestinal bleeding; VCE: video capsule endoscopy.

Table 17. Results of RCTs Assessing Capsule Endoscopy for Acute Gastrointestinal Tract Bleeding

<table>
<thead>
<tr>
<th>Study</th>
<th>Active Bleeding or Endoscopic Findings, n</th>
<th>Hospitalization, n</th>
<th>Mortality, n</th>
<th>GBS Score</th>
<th>Agreement Between CE and EGD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung et al (2016)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>68</td>
<td>68</td>
<td>68</td>
<td>68</td>
<td>68</td>
</tr>
<tr>
<td>CE</td>
<td>• “Coffee ground” material: 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Peptic ulcer with Forrest Ib stigmata: 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Forrest IIa: 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Esophageal varix: 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOC</td>
<td>• Peptic ulcer: 14</td>
<td>34</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Duodenal ulcer: 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Gastritis/duodenitis: 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Gastric or duodenal erosions: 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Mallory Weiss tear: 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gutkin et al (2013)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VCE</td>
<td>8 (67.7%) had positive findings confirmed by endoscopy; for these patients, average Rockall score was 3; average Blatchford score was 13</td>
<td>24</td>
<td>24</td>
<td>VCE data identical to EGD results (P=1.0)</td>
<td></td>
</tr>
</tbody>
</table>

CE: capsule endoscopy; EGD: esophagogastroduodenoscopy; GBS: Glasgow Blatchford score; RCT: randomized controlled trial; SOC: standard of care; VCE: video capsule endoscopy.

The purpose of the limitations tables (see Tables 18 and 19) is to display notable limitations identified in each study. This information is synthesized as a summary of the body of evidence following each table and provides the conclusions on the sufficiency of the evidence supporting the position statement.
Table 18. Study Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Duration of Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung et al (2016)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gutkin et al (2013)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

- Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.
- Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.
- Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.
- Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity, and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).
- Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true-positives, true-negatives, false-positives, false-negatives cannot be determined).

Table 19. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Selection</th>
<th>Blinding</th>
<th>Delivery of Test</th>
<th>Selective Reporting</th>
<th>Data Completeness</th>
<th>Statistical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung et al (2016)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gutkin et al (2013)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

- Selection key: 1. Selection not described; 2. Selection not random or consecutive (i.e., convenience).
- Blinding key: 1. Not blinded to results of reference or other comparator tests.
- Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.
- Data Completeness key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.
- Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison with other tests not reported.

Cohort Studies
Two 2013 studies with small cohorts of patients (range, 49 to 83 patients) have reported on the use of CE before upper endoscopy for acute GI bleeding, to triage and/or risk-stratify patients in the emergency department or hospital.34,35 These studies reported that CE provides useful information, such as identifying gross bleeding and inflammatory lesions in a substantial proportion of patients and in stratifying patients into high- or low-risk categories. However, the yield of CE in localizing the bleeding source was lower than for esophagogastroduodenoscopy, which is the standard initial evaluation for acute upper GI bleeding.
Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of wireless CE for diagnosing acute upper GI tract bleeding has not been established, a chain of evidence supporting the test's clinical utility for this indication cannot be constructed.

Section Summary: Acute Upper Gastrointestinal Tract Bleeding
Use of CE in the emergency department setting for suspected upper GI bleeding is based on efficiency (avoiding hospitalization, avoiding immediate endoscopy). Controlled studies are needed to assess further the impact of CE on health outcomes compared with standard management. Patients should be followed to their ultimate diagnosis to determine whether the use of CE versus other triage strategies or immediate endoscopy results in lower health care resource utilization.

Colon Cancer Screening
Clinical Context and Test Purpose
The purpose of wireless CE for patients who are being screened for colon cancer is to confirm a diagnosis and inform a decision to proceed to appropriate treatment.

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is patients who are undergoing colon cancer screening.

Interventions
The intervention of interest is wireless CE.

Comparators
The following test is currently being used to diagnose colon cancer: standard workup using optical colonoscopy.

Outcomes
The outcomes of interest for diagnostic accuracy include test validity (ie, sensitivity, specificity). The primary outcomes of interest for clinical utility are overall mortality and disease-specific mortality from colon cancer.

Wireless CE would be performed after an initial clinical examination. Though not completely standardized, follow-up screening for colon cancer would be based on guidelines for asymptomatic screening or for follow-up of significant screening findings.

Study Selection Criteria
Below are selection criteria for studies to assess whether a test is clinically valid.
The study population represents the population of interest. Eligibility and selection are described.

- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
Systematic Reviews
Several studies have assessed the accuracy of CE for detecting colonic lesions. Spada et al (2016) reported on a systematic review and meta-analysis of the diagnostic accuracy of CE for detecting colorectal polyps with stratified results for first- and second-generation capsules.36 Across the 14 eligible studies, the indications for endoscopy included colorectal cancer screening (n=1261 [47%]), postpolypectomy surveillance or family history of colorectal cancer (n=636 [24%]), symptoms suggestive of cancer and/or fecal occult blood test positivity (n=619 [23%]), positive imaging tests (n=136 [5%]), or other indication (n=24 [1%]). There were no missed cancers (n=11) in the series using second-generation CE (per-patient sensitivity, 100%). In series using the first-generation CE, 6 of 26 proven cancers were missed on CE (per-patient sensitivity, 77%).

Kjolhede et al (2020) reported on a systematic review and meta-analysis of the diagnostic accuracy of CE compared to colonoscopy with stratified results for polyps of any size, polyps ≥ 6 mm, and polyps ≥ 10 mm.37 Across analyzed patients in the 12 eligible studies, the indications for endoscopy included colorectal cancer screening or history of polyps or colorectal cancer (n=1200 [63.2%]), positive fecal immunochemical test (n=493 [26%]), first-degree relatives of patients with colorectal cancer (n=177 [9.3%]), or unspecified (n=28 [1.5%]). The rate of patients with an adequate bowel preparation ranged from 40% to 100%. The rates of complete CE transits ranged from 57% to 100%. The authors note that the relatively high rate of incomplete CE investigations limits the utility of CE in the colorectal cancer setting. All but 1 study was assessed to have a high risk of bias and applicability concerns for the reference standard.

Characteristics of the systematic reviews and their main findings are summarized in Tables 20 and 21, respectively.

Table 20. Characteristics of Systematic Reviews Assessing Capsule Endoscopy for Colon Cancer Screening

<table>
<thead>
<tr>
<th>Study</th>
<th>Dates</th>
<th>Trials</th>
<th>N (Range)</th>
<th>Design</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kjolhede et al (2020)</td>
<td>2009-2020</td>
<td>12</td>
<td>2199 (20 to 884)</td>
<td>Diagnostic accuracy studies</td>
<td>Per-patient sensitivity of CCE for various polyp size thresholds</td>
</tr>
</tbody>
</table>

CCE: colon capsule endoscopy.
Table 21. Results of Systematic Reviews Assessing Capsule Endoscopy for Colon Cancer Screening

<table>
<thead>
<tr>
<th>Random-Effects Model</th>
<th>Trials N</th>
<th>Outcomes</th>
<th>Effect Size</th>
<th>95% CI</th>
<th>(I^2), %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Spada et al (2016)(^\text{46})</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For ≥10 mm polyps</td>
<td>10 NR</td>
<td>Diagnostic accuracy for ≥10 mm polyps</td>
<td>Sens=80.0%</td>
<td>66% to 90.3%; Spec=96.2%</td>
<td>94.0% to 97.6%; PLR=18.6</td>
</tr>
<tr>
<td>For ≥6 mm polyps</td>
<td>7 NR</td>
<td>Diagnostic accuracy for ≥6 mm polyps using 1st-generation CCE</td>
<td>Sens=58%</td>
<td>44% to 70%; Spec=85.7%</td>
<td>80.2% to 90.0%; PLR=3.7</td>
</tr>
<tr>
<td>For ≥6 mm polyps</td>
<td>6 NR</td>
<td>Diagnostic accuracy for ≥6 mm polyps using 2nd-generation CCE</td>
<td>Sens=86%</td>
<td>82% to 89%; Spec=88.1%</td>
<td>74.2% to 95.0%; PLR=7.9</td>
</tr>
<tr>
<td>For ≥10 mm polyps</td>
<td>3 NR</td>
<td>Diagnostic accuracy for ≥6 mm polyps using 1st-generation CCE</td>
<td>Sens=54%</td>
<td>29% to 77%; Spec=97.4%</td>
<td>96.0% to 98.3%; PLR=NR</td>
</tr>
<tr>
<td>For ≥10 mm polyps</td>
<td>6 NR</td>
<td>Diagnostic accuracy for ≥6 mm polyps using 2nd-generation CCE</td>
<td>Sens=88%</td>
<td>81% to 91%; Spec=95.3%</td>
<td>91.5% to 97.5%; PLR=NR</td>
</tr>
<tr>
<td><strong>Kjolhede et al (2020)(^\text{37})</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For polyps of any size</td>
<td>4 338</td>
<td>Diagnostic accuracy for polyps of any size</td>
<td>Sens=85%</td>
<td>73% to 92%; Spec=85%</td>
<td>70% to 93%; PLR=NR</td>
</tr>
<tr>
<td>For polyps ≥6 mm</td>
<td>6 1324</td>
<td>Diagnostic accuracy for polyps ≥6 mm</td>
<td>Sens=87%</td>
<td>83% to 90%; Spec=88%</td>
<td>75% to 95%; PLR=NR</td>
</tr>
<tr>
<td>For polyps ≥10 mm</td>
<td>7 1577</td>
<td>Diagnostic accuracy for polyps ≥10 mm</td>
<td>Sens=87%</td>
<td>82% to 90%; Spec=95%</td>
<td>92% to 97%; PLR=NR</td>
</tr>
</tbody>
</table>

CCE: colon capsule endoscopy; CI: confidence interval; DOR: diagnostic odds ratio; NLR: negative likelihood ratio; NR: not reported; PLR: positive likelihood ratio; Sens: sensitivity; Spec: specificity.

**Prospective Studies**

Other recent studies by Saito et al (2015), Morgan et al (2016), Parodi (2018), and Cash et al (2021) have evaluated the diagnostic characteristics of CE, using subsequently performed colonoscopy as the reference standard.\(^\text{38,39,40,41}\). Of note, the Cash et al (2021) study randomized patients to colon CE or computed tomography (CT) colonography followed by optical colonoscopy.\(^\text{41}\). In the Saito et al (2015) study, of 66 evaluable patients, per-patient sensitivity for the detection of polyps was 94% (95% CI, 88.2% to 99.7%). In the Morgan et al (2016) study, for lesions 10 mm or larger, sensitivity of CE was 100% (95% CI, 56.1% to 100%), with a specificity of 93.0% (95% CI, 79.9% to 98.2%). For lesions 6 mm or larger, sensitivity was 93.3% (95% CI, 66.0% to 99.7%) and the specificity was 80.0% (95% CI,
62.5% to 90.9%). The Parodi (2018) study included 177 first-degree relatives of individuals with colorectal cancer and found, for lesions 6 mm or larger, a sensitivity of 91% (95% CI, 81% to 96%) and a specificity of 88% (95% CI, 81% to 93%). In the Cash et al (2021) study, data from 286 patients revealed that the proportion of enrollees with any polyp 6 mm or larger confirmed by subsequent blinded optical colonoscopy was 31.6% for colon CE versus 8.6% for CT colonography. The sensitivity and specificity of colon CE for polyps 6 mm or larger was 79.2% and 96.3%, respectively, while that of CT colonography was 26.8% and 98.9%. For polyps 10 mm or larger, the sensitivity and specificity of colon CE was 85.7% and 98.2% compared with 50% and 99.1% for CT colonography. The authors concluded that colon CE should be considered comparable or superior to CT colonography as a screening test; however, neither test was as effective as optical colonoscopy.

**Clinically Useful**
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

**Direct Evidence**
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of wireless CE for this indication were identified.

**Chain of Evidence**
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of wireless CE for diagnosing colon cancer has not been established, a chain of evidence supporting the test’s clinical utility for this indication cannot be constructed.

**Section Summary: Colon Cancer Screening**
Studies of diagnostic characteristics alone are insufficient evidence to determine the efficacy of CE for colon cancer screening. Because diagnostic performance is worse than standard colonoscopy, CE would need to be performed more frequently than standard colonoscopy to have comparable efficacy. Without direct evidence of efficacy in a clinical trial of colon cancer screening using CE, modeling studies using established mathematical models of colon precursor incidence and progression to cancer could provide estimates of efficacy in preventing colon cancer mortality. Studies of CE in screening populations are necessary to determine the diagnostic characteristics of the test in this setting.

**Lower Gastrointestinal Tract Bleeding and Major Risks for Colonoscopy or Moderate Sedation**
Clinical Context and Test Purpose
The purpose of wireless CE for patients with evidence of GI bleeding of lower GI origin and major risks for colonoscopy or moderate sedation is to visualize the colon for the detection of polyps or other sources of lower GI bleeding and inform a decision to proceed to further treatment and testing. The following PICO was used to select literature to inform this review.

**Populations**
The relevant population of interest is patients with evidence of GI bleeding of lower GI origin and major risks for colonoscopy or moderate sedation, but who could tolerate colonoscopy and moderate sedation in the event a clinically significant colon abnormality was identified with wireless CE.
Interventions
The intervention of interest is wireless CE for the visualization of the colon and detection of polyps or other sources of lower GI bleeding.

Comparators
The following reference standard is currently being used to detect colon polyps: standard workup using optical colonoscopy.

Outcomes
The outcomes of interest for diagnostic accuracy include test validity. The primary outcomes of interest are symptoms, disease status, and resource utilization that would change due to patient management decisions following wireless CE.

Beneficial outcomes resulting from a true-negative test result are avoiding unnecessary subsequent testing. Harmful outcomes resulting from a false-positive test result are unnecessary testing or therapeutic intervention. Harmful outcomes resulting from a false-negative test result are increased risk of further disease progression and missed colorectal disease.

Therefore, in the evaluation of wireless CE as a triage test, the test would need to identify precisely a group of patients that could safely forgo additional testing; therefore, the sensitivity, specificity, NPV, and negative likelihood ratio are key test validity characteristics.

Study Selection Criteria
Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
Diagnostic Accuracy Studies
Several studies have evaluated the diagnostic characteristics of CE for the detection of colon polyps in patients with evidence of lower GI bleeding (e.g., hematochezia, positive fecal occult blood test [FOBT]). Study characteristics and results are described in Table 22 and 23.

Table 22. Study Characteristics of Clinical Validity

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Population</th>
<th>Reference Standard</th>
<th>Threshold for Positive Index Test</th>
<th>Timing of Reference and Index Tests</th>
<th>Blinding of Assessors</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kobaek-Larsen et al (2017)42</td>
<td>FOBT-positive individuals participating in a CRC screening program in</td>
<td>OC adjusted by any findings from all follow-up procedures; repeat</td>
<td>Polyps &gt;9 mm within ±50% of CE measure</td>
<td>OC performed 1 day after CE</td>
<td>Investigators were blinded to both CE and OC; in the case of a second</td>
<td>RS adjusted in 75 patients due to follow-up procedures; only 50% (126)</td>
</tr>
<tr>
<td>Study</td>
<td>Study Population</td>
<td>Reference Standard</td>
<td>Threshold for Positive Index Test</td>
<td>Timing of Reference and Index Tests</td>
<td>Blinding of Assessors</td>
<td>Comments</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>-------------------------------------</td>
<td>---------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Rondonotti et al (2014)43,</td>
<td>FOBT-positive individuals participating in a CRC screening program in Italy (N=54; age range, 50 to 69 years)</td>
<td>colonoscopy was offered for suspected missed polyps</td>
<td>OC followed by colon segment re-inspection if double unblinding to CTC and CE results revealed a disparity</td>
<td>Polyps ≥6 mm</td>
<td>CTC and OC performed 15 days after CE</td>
<td>endoscopy, investigator was unblinded to CE findings</td>
</tr>
<tr>
<td>Eliakim et al (2009)44</td>
<td>Individuals with known or suspected colonic disease in Israel; 21% of patients had hematochezia or positive FOBT (N=104; mean age, 49.8 years)</td>
<td>OC</td>
<td>Polyps ≥6 mm and ≥10 mm within +50% of CE measure</td>
<td>OC performed within 10 hours of CE</td>
<td>Investigators blinded to both OC and CE</td>
<td>Initial blinding to CE and CTC results followed by double-unblinding and opportunity for re-inspection and adjustment of RS</td>
</tr>
</tbody>
</table>


Table 23. Study Results of Clinical Validity

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>CE Completion Rate, % (95% CI)</th>
<th>Sensitivity, % (95% CI)</th>
<th>Specificity, % (95% CI)</th>
<th>PLR; NLR</th>
<th>Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kobaek-Larsen et al (2017)42.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>None related to OC or CE.</td>
</tr>
<tr>
<td>All patients; CE &gt;9 mm</td>
<td>253</td>
<td>54 (48 to 60)</td>
<td>87 (83 to 91)</td>
<td>92 (89 to 95)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Complete CE and OC; CE &gt;9 mm</td>
<td>126</td>
<td>---</td>
<td>97 (94 to 100)</td>
<td>90 (85 to 95)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>All patients; OC &gt; 9 mm</td>
<td>253</td>
<td>90 (86 to 94)</td>
<td>88 (84 to 92)</td>
<td>100 (100)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Complete CE and OC; OC &gt; 9 mm</td>
<td>126</td>
<td>---</td>
<td>89 (84 to 94)</td>
<td>100 (100)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Rondonotti et al (2014)43.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>None related to OC or CE. 10 cases of mild abdominal pain and 2 cases of significant pain during CTC.</td>
</tr>
<tr>
<td>CE ≥6 mm</td>
<td>50</td>
<td>100</td>
<td>88.2 (62.2 to 97.9)</td>
<td>87.8 (70.8 to 96.0)</td>
<td>3.75; 0.06</td>
<td></td>
</tr>
<tr>
<td>CTC ≥6 mm</td>
<td>50</td>
<td>100</td>
<td>88.2 (62.2 to 97.9)</td>
<td>84.8 (67.3 to 94.3)</td>
<td>3.0; 0.07</td>
<td></td>
</tr>
<tr>
<td>Eliakim et al (2009)44</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 capsule retention; 7 cases of mild-</td>
</tr>
<tr>
<td>Study</td>
<td>N</td>
<td>CE Completion Rate, % (95% CI)</td>
<td>Sensitivity, % (95% CI)</td>
<td>Specificity, % (95% CI)</td>
<td>PLR; NLR</td>
<td>Adverse Events</td>
</tr>
<tr>
<td>-------</td>
<td>---</td>
<td>------------------------------</td>
<td>------------------------</td>
<td>------------------------</td>
<td>-----------</td>
<td>----------------</td>
</tr>
<tr>
<td>CE ≥6 mm</td>
<td>98</td>
<td>NR</td>
<td>89 (70 to 97)</td>
<td>76 (72 to 78)</td>
<td>NR</td>
<td>moderate headache, nausea, or vomiting related to CE bowel preparation.</td>
</tr>
<tr>
<td>CE ≥10 mm</td>
<td>98</td>
<td>NR</td>
<td>88 (56 to 98)</td>
<td>89 (86 to 90)</td>
<td>NR</td>
<td></td>
</tr>
</tbody>
</table>

CE: capsule endoscopy; CI: confidence interval; CTC: computed tomography colonography; NLR: negative likelihood ratio; NR: not reported; OC: optical colonoscopy; PLR: positive likelihood ratio.

1 Per-patient analysis.

Kobaek-Larsen et al (2017) reported on FOBT-positive individuals participating in a colorectal cancer screening program in Denmark.42, The reference standard consisted of optical colonoscopy (OC) adjusted by any findings from all additional follow-up procedures, including repeat endoscopy due to suspected missed polyps unblinded to CE results in 53 patients, repeated OC due to inadequate bowel preparation in 8 patients, and follow-up CT colonography in 14 patients. The CE completion rate was significantly lower than OC (p<.001), with only 50% of patients (n=126) having complete OC and CE investigations.

Rondonotti et al (2014) reported on FOBT-positive individuals participating in a colorectal cancer screening program in Italy.43, Unblinded colonoscopy, integrating OC, CT colonography, and CE results, was used as the reference standard. Investigations were completed in all patients with a positive likelihood ratio and negative likelihood ratio of 3.75 and 0.06 for CE, respectively.

Eliakim et al (2009) conducted a prospective, multicenter study evaluating CE compared to colonoscopy in individuals with known or suspected colonic disease.44, Twenty-one percent of patients had hematochezia or positive FOBT. The majority of patients were referred for OC due to a personal or family history of colorectal cancer or for colorectal cancer screening. Polyps of any size were detected in 44% of patients, with 53% identified as having adenomas. Overall colon cleanliness for CE was considered adequate in 78% of patients (95% CI, 68 to 86%).

Study relevance, design, and conduct limitations are described in Table 24 and 25.

<table>
<thead>
<tr>
<th>Study</th>
<th>Population*</th>
<th>Interventionb</th>
<th>Comparatorc</th>
<th>Outcomesd</th>
<th>Duration of Follow-Up*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kobaek-Larsen et al (2017)42.</td>
<td>4. Study did not specifically evaluate individuals with major risks for colonoscopy or moderate sedation.</td>
<td></td>
<td>2. Adjusted and/or unblinded reference standard not uniformly applied to all patients.</td>
<td>1,3. Impact of findings on health outcomes not assessed. Predictive values not reported.</td>
<td></td>
</tr>
<tr>
<td>Rondonotti et al (2014)43.</td>
<td>4. Study did not specifically evaluate individuals with major risks for colonoscopy or moderate sedation.</td>
<td></td>
<td></td>
<td>1. Impact of findings on health outcomes not assessed.</td>
<td></td>
</tr>
<tr>
<td>Eliakim et al (2009)44.</td>
<td>4. Study did not specifically evaluate individuals with major risks for colonoscopy or moderate sedation; only 21% of subjects had evidence of lower</td>
<td></td>
<td></td>
<td>1,3. Impact of findings on health outcomes not assessed. Predictive values not reported.</td>
<td></td>
</tr>
</tbody>
</table>
Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders

### Table 25. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Selection</th>
<th>Blinding</th>
<th>Delivery of Test</th>
<th>Selective Reporting</th>
<th>Data Completeness</th>
<th>Statistical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kobaek-Larsen et al (2017)[42]</td>
<td>1. Selection not described.</td>
<td>1. In case of second endoscopy for suspected missed polyps, endoscopist not blinded to results of CE.</td>
<td>1.3. Unclear how many complete investigations included patients with comparison to adjusted and/or unblinded reference standard. High loss due to low CE completion rate.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rondonotti et al (2014)[43]</td>
<td>1. Selection not described.</td>
<td>1. Endoscopist was unblinded to results of CE and CTC in event polyps were missed prior to segment reinspection.</td>
<td>2. CTC and OC performed 15 days later.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CE: capsule endoscopy; CTC: computed tomography colonography; OC: optical colonoscopy.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

- a Selection key: 1. Selection not described; 2. Selection not random or consecutive (ie, convenience).
- b Blinding key: 1. Not blinded to results of reference or other comparator tests.
- c Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.
- e Data Completeness key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.
- f Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.
Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of wireless CE for this indication were identified.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of wireless CE for detecting colon polyps in this population has not been established, a chain of evidence supporting the test’s clinical utility for this indication cannot be constructed.

Section Summary: Lower Gastrointestinal Tract Bleeding and Major Risks for Colonoscopy or Moderate Sedation
Studies evaluating the diagnostic characteristics of CE as a triage test have primarily involved colorectal cancer screening populations that have not specifically enrolled patients with major risks for optical colonoscopy or moderate sedation. The 3 studies identified have been heterogeneous in the timing of delivery of the reference standard, in the definition and blinding of the reference standard, and in the significant polyp size threshold determining a positive test result. Only 1 small study reported positive and negative likelihood ratios. Per-patient sensitivity and specificity ranged from 88% to 97% and 76% to 92%, respectively, and was generally reported with wide CIs. While 1 study reported a higher sensitivity and specificity compared to optical colonoscopy versus the defined reference standard, a consistent reference standard was not applied to all patients and carried a low combined rate of complete optical colonoscopy and CE investigations (50%). No studies assessed the impact of study findings on specific health outcomes. Adherence to recommended follow-up diagnostic or therapeutic interventions in patients with major risks for colonoscopy or moderate sedation is unknown. Studies of CE in the intended use population are necessary to determine the diagnostic characteristics of the test in the triage setting.

Incomplete Colonoscopy
Clinical Context and Test Purpose
The purpose of wireless CE for patients with an incomplete colonoscopy after adequate preparation where a complete evaluation of the colon was not technically possible is to visualize the colon for the detection of polyps and inform a decision to proceed to further treatment and testing.

The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is patients undergoing screening for colon polyps who experience an incomplete colonoscopy after adequate bowel preparation where a complete visualization of the colon was not technically possible. Factors that may contribute to incomplete colonoscopies include patient pain and discomfort, diverticulosis, tortuosity, adhesions due to prior surgeries, angulation or fixation of bowel loops, ineffective sedation, and endoscopist and technician expertise.

Interventions
The intervention of interest is wireless CE for the detection of colon polyps.
Comparators
The comparator of interest is repeat optical colonoscopy. Repeat colonoscopy following a prior incomplete procedure may be modified with adjusted endoscopic techniques, pediatric instruments, abdominal pressure and position changes, water exchange and water immersion techniques, carbon dioxide insufflation, magnetic endoscope imaging, alternate sedation methods, anesthesia assistance, and management with more experienced physicians.45,

Outcomes
The outcomes of interest for diagnostic accuracy include test validity. The primary outcomes of interest are symptoms, disease status, and resource utilization that would change due to patient management decisions following wireless CE.

Beneficial outcomes resulting from a true-negative test result are avoiding unnecessary repeat colonoscopy. Harmful outcomes resulting from a false-positive test result are unnecessary testing or therapeutic intervention. Harmful outcomes resulting from a false-negative test result are increased risk of missed colorectal disease.

Therefore, in the evaluation of wireless CE as a triage test, the test would need to identify precisely a group of patients that could safely forego additional testing; therefore, the sensitivity, specificity, NPV, and negative likelihood ratio are key test validity characteristics.

Study Selection Criteria
Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
Case Series
Studies evaluating the diagnostic characteristics of CE compared to a reference standard for the detection of colon polyps in patients with an incomplete colonoscopy following adequate bowel preparation were not identified. Several prospective case series describing the diagnostic yield of CE following incomplete colonoscopy for various indications are summarized in Table 26. Study relevance, design, and conduct limitations are described in Table 27 and 28.

Table 26. Study Characteristics and Results
<table>
<thead>
<tr>
<th>Study</th>
<th>Study Population</th>
<th>Indications for OC</th>
<th>Threshold for Significant Polyps</th>
<th>Timing of CE</th>
<th>Incremental CE Diagnostic Yield, n/N (%)</th>
<th>Complete Visualization of the Colon, n/N (%)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hussey et al (2018)⁴⁶</td>
<td>Patients aged ≥18 y who had an incomplete OC for reasons other than poor bowel preparation or suspected obstruction of the colonic lumen (N=50)</td>
<td>NR &gt;6 mm or ≥3 polyps Administered 90 min after IC</td>
<td>CE (any polyps): 19/50 (38) CE (significant polyps): 7/50 (14) CE + IC (any diagnosis): 37/50 (74)</td>
<td>CE: 38/50 (76) CE + IC: 42/50 (84)</td>
<td>CCE Findings (n): normal (13), polyps (19; 7/19 significant), inflammation (1), diverticular disease (1), angiodysplasia (1), cancer (1).</td>
<td>7 patients with significant polyps were referred for polypectomy, which detected 14 adenomas and hyperplastic polyps.</td>
<td></td>
</tr>
<tr>
<td>Baltes et al (2018)⁴⁷</td>
<td>Patients aged ≥18 y who had an incomplete OC due to failure to reach the cecum or ileo-cecal anastomosis due to looping, bowel angulation, adhesions, and intolerance of sedation or inflammation (N=81)</td>
<td>≥6 mm or ≥3 polyps Protocol A: next day CE (n=38) Protocol B: CE within 30 d (n=36)</td>
<td>CE (significant polyps): NR (24) CE + IC (significant polyps): 21/74 (28)</td>
<td>Protocol A: CE: 24/38 (63.3) CE + IC: 34/38 (89.5) Protocol B: CE: 24/36 (66.7) CE + IC: 35/36 (97.2)</td>
<td>Per protocol analysis: 74/81 due to 7 exclusions for technical failure</td>
<td>Adverse events: 1 capsule retention; 1 case of nausea and vomiting due to prep</td>
<td></td>
</tr>
<tr>
<td>Nogales et al (2017)⁴⁷</td>
<td>Patients aged ≥18 y who had an incomplete OC when cecal intubation was not achieved despite adequate bowel preparation (N=96)</td>
<td>&gt;6 mm or &gt;3 polyps Within 72 hours in 8 cases of suspected CRC. During the following week for all other patients.</td>
<td>CE (any diagnosis): 58/96 (60.4) CE (significant polyps): 25/96 (26)</td>
<td>CE: 69/96 (71.9) CE + IC: 89/96 (92.7)</td>
<td>CCE Findings (n): polyps (41; 25/41 significant), diverticula (1), colon cancer (2), angioectasia (2), solitary colonic ulcers (2). In 43/58 patients (44.8%) the new findings modified the therapeutic approach.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Study Population</td>
<td>Indications for OC</td>
<td>Threshold for Significant Polyps</td>
<td>Timing of CE</td>
<td>Incremental CE Diagnostic Yield, n/N (%)</td>
<td>Complete Visualization of the Colon, n/N (%)</td>
<td>Comments</td>
</tr>
<tr>
<td>-------</td>
<td>------------------</td>
<td>--------------------</td>
<td>-----------------------------------</td>
<td>--------------</td>
<td>------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Negreanu et al (2013)</td>
<td>Patients who are at risk for CRC who 1) refused (n=37) or failed prior OC (n=30), or 2) were unable to undergo OC because of anesthetic risk and co-morbidities (n=3) (N=70)</td>
<td>Abnormal transit (8), abdominal pain (4), anemia or overt bleeding (22), weight loss (1), average and high risk CRC screening (29), abnormal imaging or tumor markers (6)</td>
<td>&gt;6 mm or ≥ 3 polyps</td>
<td>NR</td>
<td>CE (relevant lesions): 23/67 (34) [95% CI, 21.6 to 44.1]</td>
<td>CE: 51/67 (76.1)</td>
<td>Exclusions: technical failures (3)</td>
</tr>
<tr>
<td>Pioche et al (2012)</td>
<td>Patients with an indication for OC per the recommendations of the French National Authority for Health, including symptoms or screening who had 1) colonoscopy failure due to</td>
<td>Abnormal transit (14), abdominal pain (22), anemia or overt bleeding (30), weight loss (2), CRC screening (39)</td>
<td>&gt;5 mm or ≥ 3 polyps</td>
<td>NR</td>
<td>CE (significant polyps, screening): 12/39 (30.8) [95% CI, 22.1 to 39.5]</td>
<td>CE: 89/107 (83.2) [95% CI, 76.1 to 90.3]</td>
<td>CCE Findings (n): significant polyps (20), insignificant polyps (2), diverticulosis (6), telangiectasia (1), lesions explaining symptoms (16)</td>
</tr>
</tbody>
</table>

17/23 patients with relevant lesions agreed to therapeutic interventions. 1 clinical failure (ulcerated rectal tumor) who refused OC following incomplete CE was reported.

Adverse events: capsule impaction and retention (5)
## Table 27. Study Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Population</th>
<th>Indications for OC</th>
<th>Threshold for Significant Polyps</th>
<th>Timing of CE</th>
<th>Incremental CE Diagnostic Yield, n/N (%)</th>
<th>Complete Visualization of the Colon, n/N (%)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hussey et al (2018)</td>
<td>2,3. Original indications for OC not reported.</td>
<td></td>
<td></td>
<td></td>
<td>16/68 (23.5)</td>
<td></td>
<td>events: capsule retention (6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CE (significant polyps not explaining symptoms)</td>
<td>8/68 (11.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baltes et al (2018)</td>
<td>1. It is not clear whether detection of polyps was the primary goal of CE for symptomatic patients.</td>
<td></td>
<td></td>
<td></td>
<td>36/107 (33.6) [95% CI, 24.7 to 42.5]</td>
<td></td>
<td>Management: Screening group (12) (endoscopic treatments [6], follow-up [5], refusal [1]); Negative findings (9/64) (OC - normal findings or nonsignificant lesions [5], adenomas [1]; CTC - normal findings [3]; Symptomatic group (24) (medical treatments [8], colectomy [1], endoscopic APC [1], follow-up [6], endoscopic treatments [7], refusal [1])</td>
</tr>
</tbody>
</table>

APC: Argon plasma coagulation; CCE: colon capsule endoscopy; CE: capsule endoscopy; CI: confidence interval; CRC: colorectal cancer; CTC: computed tomography colonography; IC: incomplete colonoscopy; NR: not reported; OC: optical colonoscopy.
### Table 28. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Selection</th>
<th>Blinding</th>
<th>Delivery of Test</th>
<th>Selective Reporting</th>
<th>Data Completeness</th>
<th>Statistical</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hussey et al (2018)</strong></td>
<td>1. Selection not described.</td>
<td>1. No comparison to reference standard.</td>
<td>1. Not registered.</td>
<td>2. Comparison to other tests not reported.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Baltes et al (2018)</strong></td>
<td>1. Selection not described.</td>
<td>1. No comparison to reference standard.</td>
<td>1. Not registered.</td>
<td>2. Comparison to other tests not reported.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nogales et al (2017)</strong></td>
<td>1. No comparison to reference standard.</td>
<td>1. Not registered.</td>
<td>2. Comparison to other tests not reported.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Negreanu et al (2013)</strong></td>
<td>1. No comparison to reference standard.</td>
<td>1. Timing of CE not described.</td>
<td>1. Not registered.</td>
<td>2. Comparison to other tests not reported.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CE: capsule endoscopy; IC: incomplete colonoscopy; OC: optical colonoscopy.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

- **Population key:** 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.
- **Intervention key:** 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.
- **Comparator key:** 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.
- **Outcomes key:** 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).
- **Follow-Up key:** 1. Follow-up duration not sufficient with respect to natural history of disease (true positives, true negatives, false positives, false negatives cannot be determined).
Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of wireless CE for this indication were identified.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility. Because the clinical validity of wireless CE for detecting colon polyps in this population has not been established, a chain of evidence supporting the test’s clinical utility for this indication cannot be constructed.

Section Summary: Incomplete Colonoscopy

No studies evaluating the diagnostic characteristics of CE compared to a reference standard for the detection of colon polyps in patients with an incomplete colonoscopy following adequate bowel preparation were identified. Case series describing the incremental diagnostic yield of CE varied in their reporting of original indications for OC and inclusion of symptomatic and/or screening patients.

It is unclear whether the primary goal of CE was the detection of colon polyps in symptomatic patients, as these lesions were reported as not explaining symptoms in 1 study. Successful CE completion rates were low (range, 63.3% to 83.2%) with 3/5 studies reporting full visualization of the colon for combined CE and incomplete colonoscopy in 84% to 97.2% of patients. Given the variable prevalence of significant and actionable findings for patients with mixed indications for colonoscopy, the diagnostic yield is insufficient to determine the clinical validity of the test. No studies assessed the impact of study findings on specific health outcomes. Information on adherence to recommended follow-up diagnostic or therapeutic interventions in patients with incomplete colonoscopies are limited, with several refusals and clinical failures reported. Studies of CE compared to standard management with repeat colonoscopy in the intended use population are necessary to determine the diagnostic characteristics of the test in the triage setting.
Known or Suspected Small Bowel Stricture
Clinical Context and Test Purpose
The purpose of the patency capsule for patients scheduled to undergo CE for known or suspected small bowel stricture is to confirm a diagnosis and inform a decision to proceed to CE. The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is individuals scheduled to undergo CE for known or suspected small bowel stricture. Contraindications to the use of CE include known or suspected obstruction or stricture, Zenker diverticulum, intestinal pseudo-obstruction, and motility disorders. Certain patients with known or suspected strictures of the small bowel may be at risk of retaining the capsule. Surgical removal may be necessary.

Interventions
The test being considered is a patency capsule as a technique to evaluate patients with known or suspected strictures before using wireless CE. The capsule could be used to select patients for CE instead of assessing clinical risk factors.

The use of the patency capsule has some risk itself. Published studies are small and do not provide comparative data on the incremental value of this capsule over standard clinical evaluation. In some series, the administration of the patency capsule has produced symptoms requiring hospitalization and even surgery. In a European study, Spada et al (2007) reported findings for 27 patients, 24 with CD. 51 In this study, 25 (92.6%) patients retrieved the patency capsule in their stools. Six patients complained of abdominal pain, 4 of whom excreted a nonintact capsule, and hospitalization was required in 1 patient due to the occlusive syndrome.

Comparators
The following practices are currently being used to diagnose known or suspected small bowel stricture: CE without patency capsule and alternative workup without CE.

Outcomes
The general outcomes of interest are test validity, symptoms, change in disease status, and treatment-related morbidity.

Study Selection Criteria
Below are selection criteria for studies to assess whether a test is clinically valid.

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of the diagnostic or risk category.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
Case Series
In a series from Europe, Delvaux et al (2005) reported on findings in 22 patients with suspected intestinal stricture, 15 of whom had CD. In this study, at 30 hours after ingestion, the patency capsule was detected in 17 (72.3%) patients. In all patients in whom the capsule was blocked in the small intestine, the stenosis had been suspected on CT scan or small bowel follow-through. In 3 patients, the delay in the progression of the patency capsule led to the cancellation of CE. In 3 patients, the patency capsule induced a symptomatic intestinal occlusion, which resolved spontaneously in 1 and required emergency surgery in 2. The authors commented that the current technical development of the patency capsule limits its use in clinical practice, because it did not detect stenoses undiagnosed by CT or small bowel follow-through, and the start of dissolution at 40 hours after ingestion is too slow to prevent episodes of intestinal occlusion. They also commented that a careful interview eliciting the patient’s history and symptoms remains the most useful indicator for suspicion of an intestinal stenosis.

Several studies have shown that patients who had an uncomplicated passage of the patency capsule subsequently underwent uncomplicated CE. These patients often had significant findings on CE. However, it is difficult to determine whether CE findings in these patients improved their outcomes beyond any alternative testing regimen available. In 1 of these studies, 3 of 106 patients had severe adverse events, including 1 patient who required surgery.

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of wireless CE for this indication were identified.

Chain of Evidence
Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility. Because the clinical validity of the patency capsule for diagnosing known or suspected strictures has not been established, a chain of evidence supporting the test’s clinical utility for this indication cannot be constructed.

Section Summary: Known or Suspected Small Bowel Stricture
The overall balance of harm and benefit of using the patency capsule cannot be determined from the existing studies.

Unexplained Upper Abdominal Complaints
Clinical Context and Test Purpose
The purpose of magnetic CE for patients who have unexplained upper abdominal complaints is to confirm a diagnosis and inform a decision to proceed to appropriate treatment. The following PICO was used to select literature to inform this review.

Populations
The relevant population of interest is patients with unexplained upper abdominal complaints such as upper abdominal pain and/or anemia.

Interventions
The intervention of interest is magnetic CE. Magnetic CE is indicated for visualization of the stomach of adults (≥22 years) with a body mass index <38. The device is contraindicated for use in patients...
wireless capsule endoscopy for gastrointestinal (GI) disorders

with GI obstruction, stenosis, fistula, or those with dysphagia. Other contraindications include patients with cardiac pacemakers or other implantable electronic medical devices as well as pregnant women, those <22 years of age, and those with a body mass index ≥38.

Comparators
The following practice is currently being used to evaluate upper abdominal complaints: standard workup for abdominal pain without magnetic CE.

Outcomes
The outcomes of interest for diagnostic accuracy include test validity (i.e., sensitivity, specificity). The primary outcomes of interest are symptoms and disease status that would change due to patient management decisions following magnetic CE. Follow-up for further diagnostic evaluation and surveillance for recurrence of symptoms would be immediate to weeks if no etiology is identified. Follow-up of weeks to months would be based on the disease condition identified by magnetic CE.

Study Selection Criteria
Below are selection criteria for studies to assess whether a test is clinically valid.

• The study population represents the population of interest. Eligibility and selection are described.
• The test is compared with a credible reference standard.
• If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.
• Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., receiver operator curve, area under the receiver operator curve, c-statistic, likelihood ratios) may be included but are less informative.
• Studies should also report reclassification of the diagnostic or risk category.

Clinically Valid
A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence
Diagnostic Accuracy Studies
Denzer et al (2015) prospectively evaluated a magnetically guided gastric capsule as compared to conventional gastroscopy in 189 patients with upper abdominal complaints (e.g., upper abdominal pain and/or anemia) from 2 French centers. In this study, capsule gastroscopy was performed initially followed by conventional gastroscopy, with a maximum delay of 1 day but a minimum delay of 4 hours. For conventional gastroscopy, the examination was performed blinded initially. If results of the magnetic capsule and blinded gastroscopy differed, then a subsequent unblinded gastroscopy was performed. Biopsies were taken whenever appropriate. The combined endoscopic assessment (blinded and unblinded gastroscopy) including biopsy was used as the final gold standard. The primary outcome parameters were the accuracy and the sensitivity, specificity, and predictive values of magnetically guided capsule gastroscopy compared with the final gold standard with regard to major lesions on a per-patient and per-lesion basis. Overall, 23 major lesions were discovered in 21 patients. Capsule accuracy on a per-patient basis was 90.5% (95% CI, 85.4% to 94.3%) with a specificity of 94.1% (95% CI, 89.3% to 97.1%) and a sensitivity of 61.9% (95% CI, 38% to 82%). The PPV and NPV were 56.5% (95% CI, 34.5% to 76.8%) and 95.2% (95% CI, 90.7% to 97.9%), respectively. Similar results for these values were seen on a per-lesion basis. Of the other 168 patients, 94% had minor and mostly multiple lesions; the capsule made a correct diagnosis in 88.1% (95% CI, 82.2% to 92.6%). No complications of capsule or conventional gastroscopy were noted. Patient preference for capsule use for a future gastroscopy, if indicated, was 100%. In this first large study to evaluate
magnetically guided capsule gastroscopy in patients with upper abdominal symptoms, the authors concluded that this technique was feasible in practice and clearly preferred by patients; however, further studies are needed to define its role in the clinical setting (e.g., as a filter test to stratify patients to undergo conventional gastroscopy or some other role). Of note, this non-US study reported a low sensitivity with a wide CI and provided an extremely limited discussion of the types of upper abdominal complaints experienced by enrolled patients. No discussion in terms of the severity and duration of the complaints, as well as prior testing and treatment was undertaken, which makes determination of the appropriate place in therapy for magnetic CE in patients with unexplained upper abdominal complaints difficult.

Liao et al (2016) evaluated the accuracy of magnetically controlled CE as compared with conventional gastroscopy in 350 patients with upper abdominal complaints in a prospective, multicenter, blinded comparison study conducted in China. All patients underwent magnetic CE followed by conventional gastroscopy 2 hours later, without sedation. The primary outcome of the study was an evaluation of gastric focal lesions. Overall, with conventional gastroscopy as the gold standard, magnetic CE detected gastric focal lesions in the entire stomach with 90.4% sensitivity (95% CI, 84.7% to 96.1%), 94.7% specificity (95% CI, 91.9% to 97.5%), and 93.4% accuracy (95% CI, 90.83% to 96.02%). The PPV and NPV were 87.9% (95% CI, 81.7% to 94%) and 95.9% (95% CI, 93.4% to 98.4%), respectively. Similar sensitivity and specificity results were observed with magnetic CE as compared to conventional gastroscopy when detecting focal lesions in the upper or lower stomach specifically. No lesions of significance were missed by magnetic CE. Additionally, 335 (95.7%) patients preferred magnetic CE over conventional gastroscopy and only 5 patients reported an adverse event; the majority of these events were considered to be related to gastric preparation. The authors concluded that magnetic CE detects upper abdominal focal lesions with comparable accuracy to conventional gastroscopy and is a promising alternative for screening for gastric diseases; however, similar to the prior study, this non-US study provided no discussion of the types of upper abdominal complaints experienced by patients or prior tests or treatments undertaken.

The purpose of the limitations tables (Tables 29 and 30) is to display notable limitations identified in each study. This information is synthesized as a summary of the body of evidence following each table and provides the conclusions on the sufficiency of evidence supporting the position statement.

**Table 29. Study Relevance Limitations**

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Duration of Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denzer et al (2015)&lt;sup&gt;56&lt;/sup&gt;</td>
<td>4. Study population non-U.S. (conducted in France)</td>
<td></td>
<td>1. Sensitivity is low with a wide confidence interval</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liao et al (2016)&lt;sup&gt;57&lt;/sup&gt;</td>
<td>4. Study population non-U.S. (conducted in China)</td>
<td></td>
<td>2. Conventional gastroscopy performed without sedation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

- **Population** key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.
- **Intervention** key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.
- **Comparator** key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.
- **Outcomes** key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).
- **Duration of Follow-Up** key: 1. Follow-up duration not sufficient with respect to natural history of disease (true positives, true negatives, false positives, false negatives cannot be determined).
Table 30. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Selection*</th>
<th>Blindingb</th>
<th>Delivery of Testc</th>
<th>Selective Reportingd</th>
<th>Data Completeness*</th>
<th>Statisticalf</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denzer et al (2015)56.</td>
<td>1. Selection of patients not clearly described</td>
<td>1. Final gold standard of conventional gastroscopy with biopsy was unblinded</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liao et al (2016)57.</td>
<td>1. Selection of patients not clearly described</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

* Selection key: 1. Selection not described; 2. Selection not random or consecutive (i.e., convenience).

b Blinding key: 1. Not blinded to results of reference or other comparator tests.

c Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.


e Data Completeness key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.

f Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs assessing the clinical utility of magnetic CE for this indication were identified.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Although magnetic CE has a similar diagnostic yield as conventional gastroscopy when evaluating patients with unexplained upper abdominal complaints, the sequence and chronology of testing and treatment recommended before magnetic CE needs to be defined to determine whether magnetic CE has utility to diagnose the condition.

Section Summary: Unexplained Upper Abdominal Complaints

Studies evaluating the diagnostic characteristics of magnetic CE as compared to conventional gastroscopy in the target population have generally demonstrated similar accuracy, sensitivity, and specificity, with increases in patient preference and an acceptable safety profile with the magnetic CE approach. However, the sequence and chronology of testing and treatment recommended before magnetic CE needs to be defined to determine whether magnetic CE has utility to diagnose the condition. No RCTs assessing the clinical utility of magnetic CE for this indication were identified.
Supplemental Information
The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Gastroenterology
In 2013, the American College of Gastroenterology (ACG) issued guidelines on the diagnosis and management of celiac disease. The guidelines recommended that capsule endoscopy (CE) not be used for initial diagnosis, except for patients with positive celiac-specific serology who are unwilling or unable to undergo upper endoscopy with biopsy (strong recommendation, moderate level of evidence). These guidelines were updated in 2023, with no mention of CE.

In 2018, the ACG updated its guidelines on the management of Crohn Disease (CD) in adults. It makes 2 recommendations specific to video capsule endoscopy:

• “Video capsule endoscopy (VCE) is a useful adjunct in the diagnosis of patients with small bowel Crohn disease in patients in whom there is a high index of suspicion of disease.”
• “Patients with obstructive symptoms should have small bowel imaging and/or patency capsule evaluation before VCE to decrease risk of capsule retention.”

These recommendations are based on multiple studies. Capsule endoscopy was found to be “superior to small bowel barium studies, computed tomography enterography (CTE) and ileocolonoscopy in patients with suspected CD, with incremental yield of diagnosis of 32%, 47%, and 22%, respectively...Capsule endoscopy has a high negative predictive value of 96%.”

In 2015, the ACG issued guidelines on the diagnosis and management of small bowel bleeding (including using “small bowel bleeding” to replace “obscure GI [gastrointestinal] bleeding,” which should be reserved for patients in whom a source of bleeding cannot be identified anywhere in the GI tract). As of November 2023, a guideline update is in progress. The 2015 guidelines made the following statements related to video CE (Table 31).

Table 31. Recommendations on Diagnosis and Management of Small Bowel Bleeding

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>SOR</th>
<th>LOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>“... VCE should be considered as a first-line procedure for SB evaluation after upper and lower GI sources have been excluded, including second-look endoscopy when indicated”</td>
<td>Strong</td>
<td>Moderate</td>
</tr>
<tr>
<td>“VCE should be performed before deep enteroscopy to increase diagnostic yield. Initial deep enteroscopy can be considered in cases of massive hemorrhage or when VCE is contraindicated”</td>
<td>Strong</td>
<td>High</td>
</tr>
</tbody>
</table>

GI: gastrointestinal; LOE: level of evidence; SB: small bowel; SOR: strength of recommendation; VCE: video capsule endoscopy.

In 2021, the ACG issued guidelines on colorectal cancer screening. They “suggest consideration of the following screening tests for individuals unable or unwilling to undergo a colonoscopy or FIT [fecal immunochemical testing]: flexible sigmoidoscopy, multitarget stool DNA test, CT [computed tomography] colonography, or colon capsule [capsule endoscopy]” (conditional recommendation, very low quality of evidence).

American Gastroenterological Association Institute
In 2017, the American Gastroenterological Association Institute issued guidelines on the use of CE. Table 32 summarizes the most relevant recommendations (not all recommendations are included).
Table 32. AGA 2017 Capsule Endoscopy Recommendations

<table>
<thead>
<tr>
<th>Statement number</th>
<th>Recommendation</th>
<th>Grade</th>
<th>QOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>For suspected CD, with negative ileocolonoscopy and imaging studies (CE of small bowel)</td>
<td>Strong</td>
<td>Very low</td>
</tr>
<tr>
<td>2</td>
<td>For CD and clinical features unexplained by ileocolonoscopy or imaging studies</td>
<td>Strong</td>
<td>Very low</td>
</tr>
<tr>
<td>3</td>
<td>For CD, when assessment of small-bowel mucosal healing (beyond reach of ileocolonoscopy) is needed</td>
<td>Conditional</td>
<td>Very low</td>
</tr>
<tr>
<td>4</td>
<td>For suspected small-bowel recurrence of CD after colectomy, undiagnosed by ileocolonoscopy or imaging studies</td>
<td>Strong</td>
<td>Very low</td>
</tr>
<tr>
<td>7</td>
<td>For celiac disease with unexplained symptoms despite treatment and appropriate investigations</td>
<td>Strong</td>
<td>Very low (efficacy)Low (safety)</td>
</tr>
<tr>
<td>8</td>
<td>For documented overt GI bleeding (excluding hematoemesis) and negative findings on high-quality EGD and colonoscopy</td>
<td>Strong</td>
<td>Very low</td>
</tr>
<tr>
<td>9</td>
<td>For overt, obscure bleeding episode, as soon as possible</td>
<td>Strong</td>
<td>Very low</td>
</tr>
<tr>
<td>10</td>
<td>With prior negative CE with repeated obscure bleeding, repeated studies (endoscopy, colonoscopy and/or CE)</td>
<td>Strong</td>
<td>Very low</td>
</tr>
<tr>
<td>11</td>
<td>For suspected obscure bleeding and unexplained mild chronic iron-deficiency anemia, in selected cases</td>
<td>Strong</td>
<td>Very low</td>
</tr>
<tr>
<td>12</td>
<td>For polyposis syndromes, which require small bowel studies, for ongoing surveillance</td>
<td>Conditional</td>
<td>Very low (efficacy) Low (safety)</td>
</tr>
</tbody>
</table>

Recommendations against the use of CE

<table>
<thead>
<tr>
<th>Statement number</th>
<th>Recommendation</th>
<th>Grade</th>
<th>QOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>For diagnosing CD when chronic abdominal pain or diarrhea are only symptoms, and with no evidence of biomarkers associated with CD</td>
<td>Conditional</td>
<td>Low</td>
</tr>
<tr>
<td>6</td>
<td>For diagnosing celiac disease</td>
<td>Strong</td>
<td>Very low (efficacy)Low (safety)</td>
</tr>
<tr>
<td>13</td>
<td>For routine substitution of colonoscopy</td>
<td>Strong</td>
<td>Very low</td>
</tr>
<tr>
<td>14</td>
<td>For IBD, as substitute for colonoscopy to assess extent and severity of disease</td>
<td>Strong</td>
<td>Very low (efficacy) Low (safety)</td>
</tr>
</tbody>
</table>


American Society of Gastrointestinal Endoscopy

In 2017, the American Society of Gastrointestinal Endoscopy released guidelines for the use of endoscopy in the management of suspected small bowel bleeding. These guidelines made the following recommendations on capsule endoscopy (Table 33).

Table 33. Recommendations on Use of Endoscopy to Manage Suspected Small Bowel Bleeding

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>QOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>We suggest VCE as the initial test for patients with overt or occult small-bowel bleeding. Positive VCE results should be followed with push enteroscopy if within reach or DAE.*</td>
<td>Moderate</td>
</tr>
<tr>
<td>“We suggest DAE or push enteroscopy if VCE is unavailable or nondiagnostic in patients with overt small bowel bleeding.”*</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

DAE: device-assisted enteroscopy; QOE: quality of evidence; VCE: video capsule endoscopy.

U.S. Multi-Society Task Force

The U.S. Multi-Society Task Force (2017) issued recommendations for colorectal cancer screening with representation from the ACG, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. Capsule endoscopy every 5 years received a tier 3 ranking with the following recommendation:
• "We suggest that capsule colonoscopy (if available) is an appropriate screening test when patients decline colonoscopy, FIT, FIT–fecal DNA, CT colonography, and flexible sigmoidoscopy (weak recommendation, low-quality evidence)."

In tandem with the U.S. Preventative Services Task Force (USPSTF) 2021 recommendations, the Multi-Society Task Force released a focused update to these guidelines in 2021, however, no changes were made regarding CE.67.

U.S. Preventive Services Task Force Recommendations
The USPSTF published its most recent recommendations for colorectal cancer screening in 2021.68 Colorectal cancer screening was recommended starting at age 50 years and continuing until age 75 years (A recommendation) and in adults aged 45 to 49 years (B recommendation). The USPSTF recommendation for screening for colorectal cancer does not include serum tests, urine tests, or CE for colorectal cancer screening because of the limited available evidence on these tests and because other effective tests are available.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 34.

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td>Impact of Blood Detection Capsule &quot;HemoPill Acute&quot; on the Time to Emergency Endoscopy in Case of Suspected Nonvariceal Upper Gastrointestinal Bleeding</td>
<td>72</td>
<td>Dec 2024</td>
</tr>
<tr>
<td>NCT02738359</td>
<td>Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening, in First Degree Relatives of Patients With Colorectal Neoplasia: a Prospective Randomized Study</td>
<td>3250</td>
<td>Nov 2023</td>
</tr>
<tr>
<td>NCT04307901</td>
<td>Safety of Colorectal Assessment and Tumor Evaluation by Colon Capsule Endoscopy (SOCRATEC)</td>
<td>600</td>
<td>Dec 2030</td>
</tr>
<tr>
<td>NCT05108844</td>
<td>A Randomized Controlled Trial Evaluating the Efficacy of Early Videocapsule Endoscopy Following Negative Gastroscopy in Patients Presenting With Suspected Upper Gastrointestinal Bleeding</td>
<td>70</td>
<td>Oct 2023</td>
</tr>
<tr>
<td>NCT03616041</td>
<td>Video Capsule Endoscopy for Lesion Localization and Diagnosis in Patients With Severe Hematochezia</td>
<td>50</td>
<td>Jul 2023</td>
</tr>
<tr>
<td>Unpublished</td>
<td>Capsule Endoscopy for Hemorrhage in the ER</td>
<td>24</td>
<td>Sep 2020</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References


46. Hussey M, Holleran G, Stack R, et al. Same-day colon capsule endoscopy is a viable means to assess unexplored colonic segments after incomplete colonoscopy in selected patients. United European Gastroenterol J. Dec 2018; 6(10): 1556-1562. PMID 30574326


Documentation for Clinical Review

Please provide the following documentation:
- History and physical and/or consultation notes including:
  - Reason for procedure including suspected or known diagnoses
  - Prior endoscopy or imaging reports if applicable
  - Evidence of anemia (i.e., CBC) or GI bleeding if applicable

Post Service (in addition to the above, please include the following):
- Operative/procedure report(s)
- Diagnostic radiology reports

Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.

The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0651T</td>
<td>Magnetically controlled capsule endoscopy, esophagus through stomach, including intraprocedural positioning of capsule, with interpretation and report</td>
</tr>
<tr>
<td>Type</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>91110</td>
<td>Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus through ileum, with interpretation and report</td>
</tr>
<tr>
<td></td>
<td>91111</td>
<td>Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with interpretation and report</td>
</tr>
<tr>
<td></td>
<td>91113</td>
<td>Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), colon, with interpretation and report</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>HCPCS</strong></td>
</tr>
<tr>
<td></td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

**Policy History**

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/13/2002</td>
<td>BCBSA Medical Policy adoption</td>
</tr>
<tr>
<td>10/16/2002</td>
<td>BCBSA Medical Policy adoption</td>
</tr>
<tr>
<td>11/01/2002</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>06/01/2004</td>
<td>BCBSA Medical Policy adoption</td>
</tr>
<tr>
<td>04/01/2005</td>
<td>BCBSA Medical Policy adoption Regarding the esophagus; modified, Title change</td>
</tr>
<tr>
<td>01/23/2008</td>
<td>Administrative Review Disclaimer stated added to Medical Policy.</td>
</tr>
<tr>
<td>09/25/2009</td>
<td>Policy Revision</td>
</tr>
<tr>
<td>01/11/2013</td>
<td>Policy revision with position change</td>
</tr>
<tr>
<td>12/15/2014</td>
<td>Policy title change from Wireless Capsule Endoscopy Policy revision with position change effective 2/15/2015</td>
</tr>
<tr>
<td>02/15/2015</td>
<td>Policy revision with position change</td>
</tr>
<tr>
<td>01/01/2017</td>
<td>Policy title change from Wireless Capsule Endoscopy as a Diagnostic Technique in Disorders of the Small Bowel, Esophagus, and Colon Policy revision without position change</td>
</tr>
<tr>
<td>01/01/2018</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>01/01/2019</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>02/01/2020</td>
<td>Annual review. No change to policy statement. Literature review updated.</td>
</tr>
<tr>
<td>05/01/2020</td>
<td>Administrative update. Policy statement updated.</td>
</tr>
<tr>
<td>02/01/2021</td>
<td>Annual review. Policy statement and literature updated.</td>
</tr>
<tr>
<td>08/01/2021</td>
<td>Coding update</td>
</tr>
<tr>
<td>02/01/2022</td>
<td>Annual review. Policy statement and literature updated. Policy title changed from Wireless Capsule Endoscopy to Diagnose Disorders of the Small Bowel, Esophagus, and Colon to current one. Coding update.</td>
</tr>
<tr>
<td>02/01/2023</td>
<td>Annual review. Policy statement, guidelines and literature review updated</td>
</tr>
<tr>
<td>02/01/2024</td>
<td>Annual review. No change to policy statement. Literature review updated</td>
</tr>
</tbody>
</table>

**Definitions of Decision Determinations**

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent...
with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member’s illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

### Prior Authorization Requirements and Feedback (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member’s health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member’s eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at [www.blueshieldca.com/provider](http://www.blueshieldca.com/provider).

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: [MedPolicy@blueshieldca.com](mailto:MedPolicy@blueshieldca.com)

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.
### POLICY STATEMENT

**BEFORE**

**AFTER**

<table>
<thead>
<tr>
<th>Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders 6.01.33</th>
<th>Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders 6.01.33</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Policy Statement:</strong></td>
<td><strong>Policy Statement:</strong></td>
</tr>
<tr>
<td>I. Wireless capsule endoscopy of the small bowel may be considered <strong>medically necessary</strong> when both of the following conditions are met:</td>
<td>I. Wireless capsule endoscopy of the small bowel may be considered <strong>medically necessary</strong> when both of the following conditions are met:</td>
</tr>
<tr>
<td>A. When the procedure is NOT intended for all of the below:</td>
<td>A. When the procedure is NOT intended for all of the below:</td>
</tr>
<tr>
<td>1. To evaluate of the extent of involvement of known Crohn disease or ulcerative colitis</td>
<td>1. To evaluate of the extent of involvement of known Crohn disease or ulcerative colitis</td>
</tr>
<tr>
<td>2. To evaluate the esophagus, in individuals with gastroesophageal reflux or other esophageal pathologies</td>
<td>2. To evaluate the esophagus, in individuals with gastroesophageal reflux or other esophageal pathologies</td>
</tr>
<tr>
<td>3. To evaluate other gastrointestinal (GI) diseases and conditions not presenting with GI bleeding, including but not limited to, celiac sprue, irritable bowel syndrome, lymphoid hyperplasia (risk for hereditary nonpolyposis colorectal cancer), portal hypertensive enteropathy, small bowel neoplasm, screening for colonic polyps or cancer and unexplained chronic abdominal pain</td>
<td>3. To evaluate other gastrointestinal (GI) diseases and conditions not presenting with GI bleeding, including but not limited to, celiac sprue, irritable bowel syndrome, lymphoid hyperplasia (risk for hereditary nonpolyposis colorectal cancer), portal hypertensive enteropathy, small bowel neoplasm, screening for colonic polyps or cancer and unexplained chronic abdominal pain</td>
</tr>
<tr>
<td>4. For Initial evaluation of individuals with acute upper GI bleeding</td>
<td>4. For Initial evaluation of individuals with acute upper GI bleeding</td>
</tr>
<tr>
<td>5. To evaluate individuals with evidence of lower GI bleeding and major risks for colonoscopy or moderate sedation</td>
<td>5. To evaluate individuals with evidence of lower GI bleeding and major risks for colonoscopy or moderate sedation</td>
</tr>
<tr>
<td>6. To evaluate individuals following incomplete colonoscopy</td>
<td>6. To evaluate individuals following incomplete colonoscopy</td>
</tr>
<tr>
<td>B. If the procedure is intended for any of the below:</td>
<td>B. If the procedure is intended for any of the below:</td>
</tr>
<tr>
<td>1. Suspected small bowel bleeding, and both of the following:</td>
<td>1. Suspected small bowel bleeding, and both of the following:</td>
</tr>
<tr>
<td>a. Inconclusive upper gastrointestinal (GI) endoscopy during the current episode of illness</td>
<td>a. Inconclusive upper gastrointestinal (GI) endoscopy during the current episode of illness</td>
</tr>
<tr>
<td>b. Inconclusive lower GI endoscopy (colonoscopy) during the current episode of illness</td>
<td>b. Inconclusive lower GI endoscopy (colonoscopy) during the current episode of illness</td>
</tr>
<tr>
<td>2. Initial diagnosis in individuals with suspected Crohn disease without evidence of disease on conventional diagnostic tests (such as small bowel follow-through [SBFT] and upper and lower endoscopy)</td>
<td>2. Initial diagnosis in individuals with suspected Crohn disease without evidence of disease on conventional diagnostic tests (such as small bowel follow-through [SBFT] and upper and lower endoscopy)</td>
</tr>
</tbody>
</table>
### POLICY STATEMENT
(No changes)

<table>
<thead>
<tr>
<th>BEFORE</th>
<th>AFTER</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Established diagnosis of Crohn disease, with unexpected change(s) in the course of disease or response to treatment, suggesting the initial diagnosis may be incorrect and reexamination may be indicated.</td>
<td>3. Established diagnosis of Crohn disease, with unexpected change(s) in the course of disease or response to treatment, suggesting the initial diagnosis may be incorrect and reexamination may be indicated.</td>
</tr>
<tr>
<td>4. For surveillance of the small bowel in individuals with hereditary GI polyposis syndromes, including familial adenomatous polyposis and Peutz-Jeghers syndrome.</td>
<td>4. For surveillance of the small bowel in individuals with hereditary GI polyposis syndromes, including familial adenomatous polyposis and Peutz-Jeghers syndrome.</td>
</tr>
</tbody>
</table>

II. Wireless Capsule Endoscopy is considered **investigational** if the patient's situation does not meet the criteria above.

III. The patency capsule is considered **investigational**, including use to evaluate patency of the GI tract before wireless capsule endoscopy.

IV. Magnetic capsule endoscopy is considered **investigational** for the evaluation of individuals with unexplained upper abdominal complaints and all other indications.